

AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A₃ LIGANDS

The present invention relates to the adenosine A₃ receptor ligands of
5 the general formula (I), within those preferably to the antagonists, as well as
to their salts, solvates and isomers (tautomers, desmotrops, optically active
isomers), to the pharmaceutical compositions containing them, to the use of
the compounds of the general formula (I) and their salts, solvates and
isomers, to the preparation of the compounds of the general formula (I) and
10 their salts, solvates and isomers, to the partly novel intermediates of the
general formula (II"), (III"), (IV"), (V"), (VI"), (VII"), (VIII") and (XIII")
and to the preparation thereof.

Adenosine is a well-known component of several endogenous
molecules (ATP, NAD⁺, nucleic acids). It plays an important regulatory
15 role in many physiological processes. The effect of adenosine on the heart
function was described already in 1929 (Drury and Szentgyörgyi, *Physiol.*
68:213, 1929). The identification of an increasing number of physiological
functions mediated by adenosine and the discovery of new adenosine
receptor subtypes are offering possibilities for the therapeutic application of
20 specific ligands (Poulse, S. A. and Quinn, R. J. *Bioorganic and Medicinal*
Chemistry 6:619, 1998).

To date, the receptors for adenosine have been classified into three
main classes: A₁, A₂ and A₃. The A₁ subtype is partly responsible for the
inhibition of the adenylate cyclase by coupling to G_i membrane protein, and
25 partly influences other second messenger systems. The A₂ receptor subtype
can be subdivided into two further subtypes – A_{2a} and A_{2b} –, which
stimulate the adenylate cyclase activity. The sequence of the adenosine A₃

receptors have been first identified from rat testis cDNA library. Later it was proved that it corresponds to a novel, functional adenosine receptor. The activation of the A_3 receptors is also connected with several second-messenger systems: inhibiting of adenylate cyclase, stimulating
5 phospholipase C and D.

The adenosine receptors are found in several organs and regulate their functions. Both A_1 and A_{2a} receptors play important role in the central nervous system and cardiovascular system. In the CNS, the adenosine inhibits the release of synaptic transmitters which effect is mediated by A_1
10 receptors. In the heart, the A_1 receptors also mediate the negative inotropic, chronotropic and dromotropic effects of adenosine. The adenosine A_{2a} receptors, which are located in a relatively high amount in the striatum, display functional interaction with the dopamine receptors in regulating the synaptic transmission. The A_{2a} adenosine receptors on endothelial and
15 smooth muscle cells are responsible for adenosine-induced vasodilation.

On the basis of RNA identification, the A_{2b} adenosine receptors are widely distributed in different tissues. They have been identified in almost every cell type, but its expression is the highest in the intestine and the bladder. This subtype probably also has important regulatory function in
20 the regulation of the vascular tone and plays a role in the function of mast cells.

Contrary to A_1 and A_{2a} receptors, where the tissue distribution was detected on the protein level, the presence of A_{2b} and A_3 receptors was detected on the basis of their mRNA level. Expression levels for A_3
25 adenosine receptors are rather low compared to other subtypes and they are highly species dependent. A_3 adenosine receptors are expressed primarily in the central nervous system, in the testis and in the immune system, and

appear to be involved in the modulation of the mediator release from the mast cells in immediate hypersensitivity reaction.

For therapeutic use, it is essential to ensure that the molecule does not bind, or binds only in the case of very high concentration to the A₁, A_{2a}
5 and A_{2b} sub-types of the adenosine receptor.

Our present invention relates to the compounds of the general formula (I) as well as their salts, solvates and isomers, which have high selectivity for the A₃ sub-type of the adenosine receptor.

A₃ antagonists published so far in the literature, belong to the groups
10 of flavonoides, 1,4-dihydropyridine derivatives, triazoloquinazolines, thiazolonaphthyridines and thiazolopyrimidines. Most of the effective and for the adenosine subtypes selective antagonists, however possess strong lipophilic character, and they are therefore sparingly soluble in water. This feature hinders the in vivo applicability of the compounds. In the literature
15 more and more studies are to find aiming the preparation of water soluble adenosine A₃ receptor antagonists (Ch. E. Müller et al., J. Med. Chem. 45:3440, 2002; A. Maconi et al., J. Med. Chem. 45:3579, 2002).

Patent application WO 02/096879 discloses 2-amino-3-cyanoquinoline derivatives as structurally novel type, effective A₃
20 antagonists. The compounds of the formula (1) described in patent application WO 02/096879 are A₃ antagonists with high selectivity.

In the general formula (1)

R^{1'} stands for hydrogen atom or straight or branched C₁₋₄ alkyl group;
R^{2'} stands for hydrogen atom or straight or branched C₁₋₄ alkyl group;
25 R^{3'} stands for hydrogen atom or straight or branched C₁₋₄ alkyl group, phenyl, thienyl, or furyl group, optionally substituted with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄

alkoxy group or halogen atom; a six- or five-membered heteroaromatic ring containing one, two or three nitrogen atoms, or one nitrogen atom and one oxygen atom, or one nitrogen atom and one sulphur atom, optionally substituted with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group or halogen atom;

R^{9'}, R^{10'}, R^{11'}, and R^{12'} independently stand for hydrogen atom, straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group, hydroxy group or halogen atom, or R^{9'} and R^{12'} stand for hydrogen atom and R^{10'} and R^{11'} form together a methylenedioxy group;

R^{6'} stands for hydrogen atom or a cyano group, aminocarbonyl group, C₁₋₄ alkoxy carbonyl group, or carboxy group;

R^{7'} stands for hydrogen atom or straight or branched C₁₋₄ alkyl group, phenyl, benzyl, thienyl, or furyl group, optionally substituted with methylenedioxy-group or with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group, hydroxy group, trifluoromethyl group, cyano group or halogen atom; or a six- or five-membered heteroaromatic ring containing one, two or three nitrogen atoms, or one nitrogen atom and one oxygen atom, or one nitrogen atom and one sulphur atom, optionally substituted with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group or halogen atom;

X' stands for -CH₂- group, -NH- group, -NR^{8'}- group, or sulphur atom, oxygen atom, sulphy group or sulphy group, wherein R^{8'} stands for straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group;

n' represents zero, 1 or 2;

These compounds too, have the characteristic disadvantage that they are only sparingly soluble, which hampers their development into a drug.

Our aim was to prepare A₃ ligands, within them preferably
5 antagonists, with quinoline structure, which exert strong antagonistic effect and high selectivity for the A₃ receptor, i.e. they inhibit the A₃ receptor in much lower concentration than they inhibit the A₁, A_{2a} and A_{2b} receptors. Further aims were to have stability, bioavailability, therapeutic index, toxicity and solubility data, which enable these new compounds to develop
10 into drug substances, and that the new compounds possess favourable enteric absorption to be applied orally.

We have found that the compounds of the general formula (I), -
wherein

- R¹ stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group;
15 R² stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group;
R³ stands for hydrogen atom, or a straight or branched C₁₋₄ alkyl group, C₃₋₆ cycloalkyl group, a phenyl, thienyl, or furyl group, optionally substituted with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group, or halogen atom; a six- or
20 five-membered heteroaromatic ring containing one, two or three nitrogen atoms, or a five-membered heteroaromatic ring containing one nitrogen atom and one oxygen atom, or one nitrogen atom and one sulphur atom, optionally substituted with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group, or
25 halogen atom;
R⁴ and R⁵ independently stand for hydrogen atom, C₃₋₆ cycloalkyl group, straight or branched C₁₋₄ alkyl group - optionally containing an

amino group, or an amino group substituted with one or two straight or branched C₁₋₄ alkyl group, a hydroxy group, a carboxy group, or an alkoxy group substituted with a straight or branched C₁₋₄ alkyl group -; or

5 R⁴ stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group or a benzyl group, and

 R⁵ stands for hydrogen atom, -SO₂OH group or a straight or branched C₁₋₄ acyl group, or

 R⁴ and R⁵, together with the nitrogen atom, form a group of the general
10 formula a.), wherein R⁷ and R⁸ independently stand for hydrogen atom, straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group;

 R⁶ stands for hydrogen atom or straight or branched C₁₋₄ alkyl group, phenyl, benzyl, thienyl, or furyl group, optionally substituted with methylenedioxy group, or with one or more straight or branched C₁₋₄
15 alkyl group, straight or branched C₁₋₄ alkoxy group, hydroxy group, trifluoromethyl group, cyano group or halogen atom; or a six- or five-membered heteroaromatic ring containing one, two or three nitrogen atoms, or one nitrogen atom and one oxygen atom, or one nitrogen atom and one sulphur atom, optionally substituted with one
20 or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group or halogen atom;

 X stands for -CH₂- group, -NH- group, -NR⁹- group, or sulphur atom, oxygen atom, sulpho group or sulphoxy group, wherein R⁹ stands for straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group;

25 Z stands for oxygen atom sulphur atom, -CHR¹⁰-group or -NR¹¹-group, wherein R¹⁰ stands for hydrogen atom, straight or branched C₁₋₄ alkyl group, or C₃₋₆ cycloalkyl group and R¹¹ stands for

hydrogen atom, straight or branched C₁₋₄ alkyl group, C₃₋₆ cycloalkyl group, -SO₂OH group or a straight or branched C₁₋₄ acyl group ;

n represents zero, 1 or 2;

m represents 1, 2, or 3;

5 o represents 1, 2, or 3;

p represents zero or 1;

r represents zero or 1,

and their salts, solvates, isomers (tautomers, desmotrops, optically active isomers) as well as the salts and solvates thereof fulfil the above criteria,

10 their solubility data are by far better than those of the known 2-amino-3-cyanoquinolines, and besides, they are highly active.

As shown by liquid phase NMR studies, in solution the compounds of the general formula (I) are equilibrium mixtures of the tautomeric forms (IA) and (IB). In solid phase the tautomers (IA) and (IB) can be isolated
15 separately, as the desmotrops (IA) and (IB).

According to the above findings, the present invention also relates to the desmotropic isomers (IA) and (IB). The meanings of the substituents in the general formulae (IA) and (IB) are as defined for the general formula (I).

20 The compounds of the general formula (I) may have a chiral centre depending for instance on the meaning of the set of substituents R¹, R², and R³. Thus, the invention also relates to the racemic and optically active forms of the compounds of the general formula (I) and their salts, tautomers and desmotrops.

25 Detailed meanings of the above substituents are as follows:

By a straight or branched C₁₋₄ alkyl group we mean a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary-butyl or tertiary-butyl group, preferably ethyl or methyl group.

By a straight or branched C₁₋₄ alkoxy group we mean a methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, secondary-butoxy, tertiary-butoxy, preferably ethoxy or methoxy group.

By a C₃₋₆ cycloalkyl group we mean a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group.

By a straight or branched C₁₋₄ acyl group we mean a formyl, acetyl, propionyl, 2-methyl-propionyl, or butyryl group.

By the heteroaromatic ring containing one, two or three nitrogen atoms we mean a pyrrole, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, pyridine, pyrimidine, pyridazine, pyrazine or 1,2,4-triazine ring. The ring may optionally be substituted with a C₁₋₄ alkyl group, C₁₋₄ alkoxy group, or halogen atom.

By the heteroaromatic ring containing one nitrogen atom and one oxygen- or one sulphur atom we mean an oxazole, isoxazole, thiazole or isothiazole ring. The ring may optionally be substituted with a C₁₋₄ alkyl group, C₁₋₄ alkoxy group, or halogen atom.

The a.) group preferably represents a pyrrolidino, piperidino, piperazino, 4-methylpiperazino, 4-formylpiperazino, 4-sulfonylpiperazino or morpholino group.

By salts of the compounds of the general formula (I) we mean salts formed with inorganic or organic acids and bases. Preferred salts are given with pharmaceutically accepted acids, as for instance hydrochloric acid, sulphuric acid, ethanesulphonic acid, tartaric acid, malic acid, citric acid, fumaric acid, and with pharmaceutically accepted bases, as for instance

sodium hydroxide, potassium hydroxide, and ethanolamine. Salts used for purification or isolation, as for instance the methanesulphonate or tetrafluoroborate salts are also subjects of the invention.

By solvates we mean solvates given with various solvents, as for instance with water or ethanol.

A favoured group of the compounds of the general formula (I) are those, wherein

R¹ stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group;

R² stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group;

10 R³ stands for hydrogen atom, or a straight or branched C₁₋₄ alkyl group, C₃₋₆ cycloalkyl group, a phenyl, thienyl, or furyl group, optionally substituted with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group, or halogen atom;

15 R⁴ and R⁵ independently stand for hydrogen atom, C₃₋₆ cycloalkyl group, straight or branched C₁₋₄ alkyl group - optionally containing an amino group, or an amino group substituted with one or two straight or branched C₁₋₄ alkyl group, a hydroxy group, a carboxy group, or an alkoxy group substituted with a straight or branched C₁₋₄ alkyl group -; or

20 R⁴ stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group or a benzyl group, and

R⁵ stands for hydrogen atom, -SO₂OH group or a straight or branched C₁₋₄ acyl group, or

25 R⁴ and R⁵, together with the nitrogen atom, form a group of the general formula a.), wherein R⁷ and R⁸ independently stand for hydrogen atom, straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group;

R⁶ stands for hydrogen atom or straight or branched C₁₋₄ alkyl group, phenyl, benzyl, thienyl, or furyl group, optionally substituted with a methylenedioxy group, or with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group, hydroxy group, trifluoromethyl group, cyano group, or halogen atom; or a six- or five-membered heteroaromatic ring containing one, two or three nitrogen atoms, or one nitrogen atom and one oxygen atom, or one nitrogen atom and one sulphur atom, optionally substituted with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group or halogen atom;

X stands for -CH₂- group, -NH- group, -NR⁹- group, or sulphur atom, oxygen atom, sulpho group or sulphoxy group, wherein R⁹ represents a straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group;

Z stands for oxygen atom, sulphur atom, -CHR¹⁰-group or -NR¹¹-group, wherein R¹⁰ represents hydrogen atom, straight or branched C₁₋₄ alkyl group, or C₃₋₆ cycloalkyl group and R¹¹ stands for hydrogen atom, straight or branched C₁₋₄ alkyl group, C₃₋₆ cycloalkyl group, -SO₂OH group or formyl group;

n represents zero, 1 or 2;

m represents 1, 2, or 3;

o represents 1, 2, or 3;

p represents zero or 1;

r represents zero or 1,

and their salts, solvates, isomers (tautomers, desmotrops, optically active isomers) as well as the salts and solvates thereof.

A specially favoured group of the compounds of the general formula (I) are those, wherein

R¹ stands for hydrogen atom or methyl group;

R² stands for hydrogen atom or methyl group;

5 R³ stands for phenyl, thienyl, or furyl group;

R⁴ and R⁵ independently stand for hydrogen atom, C₃₋₆ cycloalkyl group, straight or branched C₁₋₄ alkyl group - optionally containing an amino group, or an amino group substituted with one or two straight or branched C₁₋₄ alkyl group, a hydroxy group, a carboxy group, or
10 an alkoxy group substituted with a straight or branched C₁₋₄ alkyl group -; or

R⁴ stands for hydrogen atom or a straight or branched C₁₋₄ alkyl alkyl group or a benzyl group, and

15 R⁵ stands for hydrogen atom, -SO₂OH group or a straight or branched C₁₋₄ acyl group, or

R⁴ and R⁵, together with the nitrogen atom, form a group of the general formula a.), wherein R⁷ and R⁸ independently stand for hydrogen atom, straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group;

20 R⁶ stands for 4-methoxyphenyl, 3-methylphenyl, 3-methoxyphenyl, 3,4-methylenedioxyphenyl group, 4-fluorophenyl, 2-thienyl or 2-furyl group;

X stands for -NH- group, or oxygen atom;

Z stands for oxygen atom, sulphur atom, -CH₂- group, -NH- group or -NR¹¹- group -wherein R¹¹ represents a straight or branched C₁₋₄ alkyl group, C₃₋₆ cycloalkyl group, -SO₂OH group or formyl group;
25 and

n represents 1;

m represents 2;
 o represents 2;
 p represents zero;
 r represents zero,

- 5 and their salts, solvates, isomers (tautomers, desmotrops, optically active isomers) as well as the salts and solvates thereof.

Especially favoured are the following compounds, which fulfil the above criteria:

- 10 4-Methoxy-N-[6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl]-benzamide
4-Methoxy-N-[6-(4-methylpiperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide
4-Methoxy-N-(6-dimethylamino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide
 15 3,4-Methylenedioxy-N-(6-dimethylamino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide
4-Fluoro-N-(6-dimethylamino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide
 20 4-Methoxy-N-(6-(piperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl)benzamide
4-Methoxy-N-(6-amino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide
N-[4-(Benzylamino)-3-cyano-6-(4-formylpiperazin-1-yl)quinolin-2-yl]-4-methoxybenzamide
 25 4-{4-(Benzylamino)-3-cyano-2-[(4-methoxybenzoyl)amino]quinolin-6-yl}piperazine-1-sulfonic acid

N-{3-Cyano-6-(formylamino)-4-[(2-thienylmethyl)amino]quinolin-2-yl}-4-methoxybenzamide

5 N-{3-Cyano-6-(formylamino)-4-[(2-thienylmethyl)amino]quinolin-2-yl}-1,3-benzodioxole-5-carboxamide

N-[4-(Benzylamino)-3-cyano-6-(formylamino)quinolin-2-yl]-1,3-benzodioxole-5-carboxamide

10 N-[4-(Benzylamino)-3-cyano-6-(formylamino)quinolin-2-yl]-4-methoxybenzamide

N-{4-(Benzylamino)-3-cyano-6-[formyl(methyl)amino]quinolin-2-yl}-4-methoxybenzamide

15 N-{3-Cyano-6-[formyl(methyl)amino]-4-[(2-thienylmethyl)amino]quinolin-2-yl}-4-methoxybenzamide

20 {3-Cyano-2-[(4-methoxybenzoyl)amino]-4-[(2-thienylmethyl)amino]quinolin-6-yl} methylsulfamic acid

{4-(Benzylamino)-3-cyano-2-[(4-methoxybenzoyl)amino]quinolin-6-yl} methylsulfamic acid

25 {4-(Benzylamino)-3-cyano-2-[(4-methoxybenzoyl)amino]quinolin-6-yl} sulfamic acid

[2-[(1,3-Benzodioxol-5-ylcarbonyl)amino]-4-(benzylamino)-3-cyanoquinolin-6-yl] sulfamic acid

30 {2-[(1,3-Benzodioxol-5-ylcarbonyl)amino]-3-cyano-4-[(2-thienylmethyl)amino]quinolin-6-yl} sulfamic acid

35 {3-Cyano-2-[(4-methoxybenzoyl)amino]-4-[(2-thienylmethyl)amino]quinolin-6-yl} sulfamic acid

and

their salts, solvates, isomers (tautomers, desmotrops), as well as the salts and solvates thereof.

The compounds of the general formula (I) according to the present invention as well as their salts, solvates, and isomers (tautomers, desmotrops, optically active isomers) and the salts, solvates thereof, display suitable solubility, therefore they can favourably be used as active substances of pharmaceutical compositions.

Solubility values in water and in aqueous buffer solutions (pH = 6.5 and 7.5) for the compounds of the formula (I) of patent application WO 02/096879 are less than 1 mg/L, whereas those for the compounds of the general formula (I) of the present invention are between 1-200 mg/L.

The present invention also relates to pharmaceutical compositions containing as active principles the compounds of the general formula (I) or their isomers (tautomers, desmotrops, optically active isomers), salts or solvates, which are preferably oral compositions, but inhalable, parenteral and transdermal formulations are also subjects of the invention. The above pharmaceutical compositions may be solids or liquids, such as tablets, pellets, capsules, patches, solutions, suspensions or emulsions. Solid compositions, first of all tablets and capsules are preferred.

The above pharmaceutical compositions are prepared by applying usual pharmaceutical auxiliary materials and by using standard methods.

The compounds of the general formula (I) can be used for the treatment of pathologies, where A_3 receptor plays a role in the development of the disease.

The compounds of the present invention having selective activity on the A_3 receptor can be used in the therapeutic and/or preventive treatment of disfunctions of the heart, kidney, respiratory system, central nervous system. They inhibit the protective effect of adenosine in growing tumor cells, prevent mast cell degranulation, inhibit the cytokine production,

reduce the intraocular pressure, inhibit the $\text{TNF}\alpha$ release, inhibit the migration of eosinophils, neutrophils and other immune cells, inhibit the bronchoconstriction and plasma extravasation.

Based on these effects, adenosine A_3 receptor antagonists of the present invention may be therapeutically useful as antiinflammatory, antiasthmatic, antiischemic, antidepressant, antiarrhythmic, renal protective, antitumor, antiparkinson and cognitive enhancing drugs. They also may be useful in the treatment or prevention of myocardial reperfusion injury, chronic obstructive pulmonary disease (COPD) and adult respiratory distress syndrome (ARDS) including chronic bronchitis, pulmonary emphysema or dyspnea, allergic reactions (e.g. rhinitis, poison ivy induced responses, urticaria, scleroderma, arthritis) other autoimmune diseases, inflammatory bowel disease, Addison's disease, Crohn's disease, psoriasis, rheumatism, hypertension, neurological function disorders, glaucoma and diabetes (K. N. Klotz, Naunyn-Schmiedberg's Arch. Pharmacol. 362:382, 2000; P. G. Baraldi és P. A. Borea, TiPS 21:456, 2000).

The compounds of the present invention may be preferably used for the manufacture of a pharmaceutical composition for the treatment of diseases such as asthma, COPD and ARDS, glaucoma, tumor, allergic and inflammatory diseases, ischemia, hypoxia, arrhythmia and renal diseases.

The present invention relates furthermore to the use of the compounds of the general formula (I) in the treatment of the above pathologies. The suggested daily dose is 0.1 - 1000 mg active ingredient, depending on the nature and severeness of the disease and on the sex, weight etc. of the patient.

A further subject of the invention is the preparation of the compounds of the general formula (I).

The substituents in the formulae of the intermediates and reagents of the general formulae (I"), (II"), (III"), (IV"), (V"), (VI"), (VII"), (VIII"), (IX"), (X"), (XI"), (XII"), (XIII") and (XIV") have the meanings as follows.

R^{1"} stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group;

R^{2"} stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group;

R^{3"} stands for hydrogen atom, or a straight or branched C₁₋₄ alkyl group,

C₃₋₆ cycloalkyl group, a phenyl, thienyl, or furyl group, optionally

substituted with one or more straight or branched C₁₋₄ alkyl group,

straight or branched C₁₋₄ alkoxy group, or halogen atom; a six- or

five-membered heteroaromatic ring containing one, two or three

nitrogen atoms, or a five-membered heteroaromatic ring containing

one nitrogen atom and one oxygen atom, or one nitrogen atom and

one sulphur atom, optionally substituted with one or more straight or

branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group, or

halogen atom;

R^{4"} and R^{5"} independently stand for hydrogen atom, C₃₋₆ cycloalkyl group,

straight or branched C₁₋₄ alkyl group - optionally containing an

amino group, or an amino group substituted with one or two straight

or branched C₁₋₄ alkyl group, a hydroxy group, a carboxy group, or

an alkoxy group substituted with a straight or branched C₁₋₄ alkyl

group –or a protective group; or

R^{4"} stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group

or a benzyl group, and

R^{5"} stands for hydrogen atom, –SO₂OH group or a straight or branched

C₁₋₄ acyl group or a protective group, or

$R^{4''}$ and $R^{5''}$, together with the nitrogen atom, form a nitro group or a group of the general formula a.), wherein $R^{7''}$ and $R^{8''}$ independently stand for hydrogen atom, straight or branched C_{1-4} alkyl group or C_{3-6} cycloalkyl group;

5 $R^{6''}$ stands for hydrogen atom or straight or branched C_{1-4} alkyl group, phenyl, benzyl, thienyl, or furyl group, optionally substituted with methylenedioxy group, or with one or more straight or branched C_{1-4} alkyl group, straight or branched C_{1-4} alkoxy group, hydroxy group, trifluoromethyl group, cyano group or halogen atom; or a six-
10 or five-membered heteroaromatic ring containing one, two or three nitrogen atoms, or one nitrogen atom and one oxygen atom, or one nitrogen atom and one sulphur atom, optionally substituted with one or more straight or branched C_{1-4} alkyl group, straight or branched C_{1-4} alkoxy group or halogen atom;

15 X'' stands for $-CH_2-$ group, $-NH-$ group, $-NR^{9''}$ group, or sulphur atom, oxygen atom, sulpho group or sulphony group, wherein $R^{9''}$ stands for straight or branched C_{1-4} alkyl group or C_{3-6} cycloalkyl group;

Z'' stands for oxygen atom sulphur atom, $-CHR^{10''}$ -group or $-NR^{11''}$ -group, wherein $R^{10''}$ stands for hydrogen atom, straight or branched C_{1-4} alkyl group, or C_{3-6} cycloalkyl group and $R^{11''}$ stands for
20 hydrogen atom, straight or branched C_{1-4} alkyl group, C_{3-6} cycloalkyl group, $-SO_2OH$ group, a straight or branched C_{1-4} acyl group or a protective group;

$R^{12''}$ stands for a straight or branched C_{1-3} alkylgroup;

25 Y'' represents a living group;

n'' represents zero, 1 or 2;

m'' represents 1, 2, or 3;

o" represents 1, 2, or 3;

p" represents zero or 1;

r" represents zero or 1,

A further subject of the invention is the preparation of the
 5 compounds of the general formula (I) and of the partly novel intermediates
 of the general formulae (I"), (II"), (III"), (IV"), (V"), (VI"), (VII"), (VIII"),
 and (XIII").

In the process according to the invention

v.) the bis-carboxamide of the general formula (II") is selectively
 10 hydrolysed and if desired the protective group removed, or

v/i.) for the preparation of a compound of the general formula (I),
 wherein R⁴ stands for hydrogen atom, a straight or branched C₁₋₄ alkyl
 group or benzyl group and R⁵ stands for a straight or branched C₁₋₄ acyl
 group, or R⁴ and R⁵ together with the nitrogen atom form a group of the
 15 general formula a.), wherein Z stands for a -NR¹¹ group, where R¹¹ stands
 for a straight or branched C₁₋₄ acyl group and R¹, R², R³, R⁶, R⁷, R⁸, R⁹, X,
 n, m, o, p and r are as defined above,

a compound of the general formula (I), wherein R⁴ stands for
 hydrogen atom, a straight or branched C₁₋₄ alkyl group or benzyl group and
 20 R⁵ stands for hydrogen atom, or R⁴ and R⁵ together with the nitrogen atom
 form a group of the general formula a.), wherein Z stands for -NH group
 and R¹, R², R³, R⁶, R⁷, R⁸, R⁹, X, n, m, o, p and r are as defined above,

is acylated with a compound of the general formula R¹²"COY",
 wherein R¹²" and Y" are as defined above, or

v/ii.) for the preparation of a compound of the general formula (I), wherein
 25 R⁴ stands for hydrogen atom, a straight or branched C₁₋₄ alkyl group or
 benzyl group and R⁵ stands for -SO₂OH group, or R⁴ and R⁵ together with

the nitrogen atom form a group of the general formula a.), wherein Z stands for $-\text{NR}^{11}$ - group, where R^{11} stands for $-\text{SO}_2\text{OH}$ group and $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{X}, \text{n}, \text{m}, \text{o}, \text{p}$ and r are as defined above,

a compound of the general formula (I), wherein R^4 stands for
 5 hydrogen atom, a straight or branched C_{1-4} alkyl group or benzyl group and R^5 stands for hydrogen atom, or R^4 and R^5 together with the nitrogen atom form a group of the general formula a.), wherein Z stands for $-\text{NH}-$ group and $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{X}, \text{n}, \text{m}, \text{o}, \text{p}$ and r are as defined above,

is reacted with a pyridine- SO_3 complex, or with ClSO_3H , or

10 v/iii.) for the preparation of a compound of the general formula (I), wherein R^4 stands for hydrogen atom, a straight or branched C_{1-4} alkyl group or benzyl group and R^5 stands for $-\text{SO}_2\text{OH}$ group and $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{X}, \text{Z}, \text{n}, \text{m}, \text{o}, \text{p}$ and r are as defined above,

a compound of the general formula (XIII"), wherein $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^6,$
 15 R^9, X , and n are as defined above

is reacted with $\text{Na}_2\text{S}_2\text{O}_4$ or NaHSO_3 ,

or

is reduced and the compound of the general formula (XIV"), thus
 obtained, wherein $\text{R}^{4''}$ stands for hydrogen atom and $\text{R}^{1''}, \text{R}^{2''}, \text{R}^{3''}, \text{R}^{6''}, \text{R}^{9''},$
 20 X'' , and n'' , are as defined above, is sulphated with a pyridine- SO_3 complex
 or with ClSO_3H ,

if desired after transforming the $\text{R}^{4''}$ hydrogen atom into a straight or
 branched C_{1-4} alkyl group or a benzyl group, or

v/iv.) for the preparation of a compound of the general formula (I), wherein
 25 R^4 stands for hydrogen atom, C_{3-6} cycloalkyl group, benzyl group, straight
 or branched C_{1-4} alkyl group - optionally containing an amino group, or an
 amino group substituted with one or two straight or branched C_{1-4} alkyl

group, a hydroxy group, a carboxy group, or an alkoxy group substituted with a straight or branched C₁₋₄ alkyl group- and R⁵ stands for hydrogen atom, or

R⁴ and R⁵, together with the nitrogen atom, form a group of the general formula a.), wherein R⁷ and R⁸ independently stand for hydrogen atom,
5 straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group and Z stands for -NR¹¹ group, where R¹¹ stands for hydrogen atom,

removing the protective group of a compound of the general formula (I''), wherein

10 R^{4''} stands for hydrogen atom, C₃₋₆ cycloalkyl group, benzyl group, straight or branched C₁₋₄ alkyl group - optionally containing an amino group, or an amino group substituted with one or two straight or branched C₁₋₄ alkyl group, a hydroxy group, a carboxy group, or an alkoxy group substituted with a straight or branched C₁₋₄ alkyl group - and R^{5''} stands for a protective
15 group, or

R^{4''} and R^{5''}, together with the nitrogen atom, form a group of the general formula a''), wherein R^{7''} and R^{8''} independently stand for hydrogen atom, straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group and Z stands for -NR^{11''} group, where R^{11''} stands for a protecting group,

20 and -if desired- the substituents of the resulting compound of the general formula (I) are transformed into each other by known methods, and/or the the compound of the general formula (I) thus obtained is transformed into its salt or solvate, or liberated from its salt or solvate and -if desired- resolved into its optically active isomers and -if desired- a given desmotrop
25 is transformed into an other desmotropic form.

As for agents for the selective hydrolysis, alkali hydroxides, preferably potassium hydroxide and/or sodium hydroxide dissolved in an

alcohol, preferably in methanol can be used, but other agents known in the organic chemistry helping the amide hydrolysis, can also be applied.

The selective hydrolysis can be carried out in a broad temperature range, preferable is the range between 20 °C and 100 °C.

5 The reaction v/i.) can be performed using an ester derivative of the appropriate acid at elevated temperature or using an activated acid derivative (e.g. acid-halogenid) at room temperature or elevated temperature applying a suitable base (e.g. triethylamine).

10 The reaction v/ii.) can be performed using pyridine-SO₃ complex in a suitable solvent (preferably in pyridine) or using ClSO₃H in a suitable solvent (preferably in pyridine or chloroform) applying a strong organic base (like DBU) or an inorganic base (like K₂CO₃) at room temperature or elevated temperature.

15 The reaction v/iii.) can be performed in an appropriate aqueous alkaline solution of the nitro compound using an excess of Na₂S₂O₄ or NaHSO₃ as reagent at room temperature or at elevated temperature (100°).

20 According to a variation of the reaction v/iii.) the nitro derivative is reduced by any of the known methods and the resulting amino derivative is alkylated or benzylated first under known reductive alkylation or benzylation conditions and the alkylamino or benzylamino derivatives, thus obtained will be sulphated as described under ii.).

25 The protective group may be any known protective group. Examples of protecting groups, as well as methods for protecting and deprotecting various functional groups are given in "Protective Groups in Organic Synthesis", Green et al., 2nd Edition *John Wiley & Sons, Inc, New York.,

1991. Preferred protective groups are Boc, ethoxycarbonyl, benzyloxycarbonyl, etc, most preferably benzyl group.

The substituents of the compounds of the general formula (I) can be transformed into each other by known methods (Comprehensive Organic Transformation, R. C. Larock, VCH Publisher, New York, 1989).

The salts can be prepared by adding one equivalent of the acid to the alcoholic, preferably ethanol solution of the base and diluting the solution with diethyl ether and finally filtering off and drying the resulting crystals.

The compounds of the general formula (II') -wherein the meanings of $R^{1''}$, $R^{2''}$, $R^{3''}$, $R^{4''}$, $R^{5''}$, $R^{6''}$, $R^{7''}$, $R^{8''}$, X , Z , n , o , p , r and m are as defined above- can be prepared by several known methods, among them by the method demonstrated on reaction scheme 1., by acylation of the compounds of formula (III'') by an acylation method known from the organic chemistry. As for acylating agent preferably an acid chloride, for acid binding agent triethyl amine and/or pyridine can be used, but other compounds known as acid binders can also be applied.

The compounds of the general formula (III'') -wherein the meanings of $R^{1''}$, $R^{2''}$, $R^{3''}$, $R^{4''}$, $R^{5''}$, $R^{6''}$, $R^{7''}$, $R^{8''}$, X , Z , n , o , p , r and m are the same as defined above- can be prepared from the compounds of formula (IV''), by methods known per se (Nan Zhang, Bioorg. and Med. Chem. Lett., 10, 2825, 2000).

The compounds of the general formula (IV'') -wherein the meanings of $R^{4''}$, $R^{5''}$, $R^{6''}$, $R^{7''}$, $R^{8''}$, X , Z , r , o , p and m are as defined above- can be

prepared from the compounds of formula (V"), by methods known per se (D.L. Leysen, J. Heterocyclic Chem., 24, 1611, 1987).

The compounds of the general formula (V") -wherein the meanings of R^{4"}, R^{5"}, R^{7"}, R^{8"}, Z", r", o", p" and m" are as defined above- can be prepared from the compounds of formula (VI"), by methods known per se (Pfizer (Inc) USP 4,175,193).

The compounds of the general formula (VI") -wherein the meanings of R^{4"}, R^{5"}, R^{7"}, R^{8"}, Z", r", o", p" and m" are as defined above- can be prepared from the compounds of formula (VII"), by methods known per se (D.L. Leysen, J. Heterocyclic Chem., 24, 1611, 1987).

The compounds of the general formula (VII") -wherein the meanings of R^{4"}, R^{5"}, R^{7"}, R^{8"}, Z", r", o", p" and m" are as defined above- can be prepared from the compounds of formula (VIII"), by methods known per se (D. H. Klaubert and J. H. Sellstedt, J. Med. Chem, 24, 742, 1981), or are products on the market, such as the compound where R^{4"} and R^{5"} together with the nitrogen atom form a nitro group

The compounds of the general formula (VIII") -wherein the meanings of R^{4"}, R^{5"}, R^{7"}, R^{8"}, Z", r", o", p" and m" are as defined above- can be prepared from the compounds of formula (IX"), by methods known per se (J. H. Hutchinson and J. J. Cook, J. Med. Chem. 39, 4583, 1996).

The compounds of the general formulae (I), (I') (II"), (III"), (IV"), (V"), (VI"), (VII"), (VIII"), (XIII") and (XIV") according to the invention, as well as their preparation and biological activity are demonstrated by the examples below, without limiting the claims to the examples.

Example 1.

4-Methoxy-N-[6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide

5 In the general formula (I) R¹ and R² stand for hydrogen atom, R³ for phenyl group, group a.) for morpholino group, R⁶ for 4-methoxyphenyl group.

a.) 2-Nitro-5-(morpholin-4-yl)benzoic acid:

10 The mixture of 5 g of 2-nitro-5-chlorobenzoic acid and 15 ml of morpholine is stirred at 120 °C for 6 hours. To the reaction mixture 150 ml of ethyl acetate is added. The precipitated yellow crystalline material is filtered off, dissolved in 15 ml of water. The pH of the mixture is adjusted to 6 with acetic acid. The precipitated material is
15 filtered off, washed with water and dried, to obtain 4.2 g of the title compound. Mp.: 172 °C.

¹H-NMR (DMSO-d₆) 7.85 ppm (m, 1H), 7.0-6.9 (m, 2H), 3.67 (m, 4H), 2.85 (m, 4H).

20 b.) 2-Amino-5-(morpholin-4-yl)benzoic acid:

The mixture of 6 g of 2-nitro-5-(morpholin-4-yl)benzoic acid, 15 ml of cyclohexene and 3 g of Pd/C (10%) is heated under reflux conditions in 120 ml of ethanol for 6 hours. The hot reaction mixture is filtered through celite filter. The filtrate is evaporated to obtain 4.8 g of the title
25 compound. M.p.: 242 °C.

¹H-NMR (DMSO-d₆) 7.25 ppm (m, 1H), 6.96 (m, 1H), 6.62 (m, 1H), 3.69 (m, 4H), 2.85 (m, 4H).

c.) 5-(Morpholin-4-yl)isatoic anhydride:

To the mixture of 8.9 g of 2-amino-5-(morpholin-4-yl)benzoic acid in 60 ml of dioxane, under stirring and external cold water cooling 10 ml of diphosgene is added dropwise. The mixture is heated under reflux conditions for 4 hours. From the cold reaction mixture the solid material is filtered off, washed with 50 ml of ether. The product is stirred for 5 minutes in the mixture of 50 ml of methanol and 5 ml of triethylamine, it is filtered off and washed with 30 ml of methanol. After drying 7 g of the title product is obtained, m.p.: 235 °C.

¹H-NMR (DMSO-d₆) 7.8ppm (m, 1H), 6.78 (m, 1H), 6.66 (m, 1H), 3.73 (m, 4H), 2.92 (m, 4H).

d.) 2-Amino-3-cyano-4-hydroxy-6-(morpholin-4-yl)quinoline:

4 g of malonitrile is dissolved in 50 ml of dimethylformamide. To the solution, in several portions, 2.4 g of 60% oily dispersion of sodium hydride are added. To the clear solution 8 g of 5-(morpholin-4-yl)isatoic anhydride is added and the mixture is stirred at room temperature for 10 hours. The reaction mixture is diluted with 70 ml of water and extracted with 2 X 30 ml of ethyl acetate. The aqueous phase is evaporated in vacuum, the solid residue is dissolved in 20 ml of water, the pH is adjusted to 6 with acetic acid. The precipitated material is filtered off, washed with water. After drying 6.5 g of the title compound is obtained, m.p.: 291 °C.

¹H-NMR (DMSO-d₆) 7.27ppm (m, 1H), 7.14 (m, 1H), 7.03 (m, 1H), 3.74 (m, 4H), 3.12 (m, 4H).

e.) 2-Amino-3-cyano-4-chloro-6-(morpholin-4-yl)quinoline:

The mixture of 1.7 g of 2-amino-3-cyano-4-hydroxy-6-(morpholin-4-yl)quinoline and 3.4 ml of phosphoryl chloride is stirred at 120 °C for 4 hours. The cooled reaction mixture is poured onto 30 g of ice, the pH of the mixture is adjusted to 8 with 10% sodium hydroxide solution, and the precipitated material is filtered off. After drying 1.5 g of the title compound is obtained, m.p.: 206 °C.

¹H-NMR (DMSO-d₆) 7.69 ppm (m, 1H), 7.49 (m, 1H), 7.08 (m, 1H), 6.83 (s, 2H), 3.74 (m, 4H), 3.08 (M, 4H).

f.) 2-Amino-3-cyano-4-benzylamino-6-(morpholin-4-yl)quinoline:

3 g of 2-amino-3-cyano-4-chloro-6-(morpholin-4-yl)quinoline and 6 ml of benzylamine are stirred at 125 °C for 3 hours. The reaction mixture is poured onto 30 ml of water. The precipitated material is filtered off, washed with 20 ml of water. After drying 2.3 g of the title compound is obtained, m.p.: 202 °C.

¹H-NMR (DMSO-d₆) 8.14 ppm (m, 1H), 7.5-7.2 (m, 8H), 5.85 (s, 2H), 5.04 (d, 2H), 3.65 (m, 4H), 3.1 (m, 4H).

g.) 4-Methoxy-N-(4-methoxybenzoyl)-N-(6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl)benzamide:

To the solution of 0.4 g of 2-amino-3-cyano-4-benzylamino-6-(morpholin-4-yl)quinoline in 2 ml of pyridine, 0.4 ml of 4-methoxybenzoyl chloride is added under stirring and cooling. The reaction mixture is stirred at 80 °C for 8 hours, and then poured onto

5 ml of ice-water. The precipitated material is filtered off, washed twice with 3 ml of water. After drying 0.53 g of the title compound is obtained, m.p.: 157 °C.

¹H-NMR (DMSO-d₆) 8.92 ppm (t, 1H), 8.32 (m, 4H), 7.61 (m, 3H),
5 7.38 (m, 5H), 7.12 (m, 4H), 5.1 (d, 2H), 3.82 (m, 8H).

h.) 4-Methoxy-N-[(6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl)]benzamide

To the solution of 2.3 g of 4-methoxy-N-(4-methoxybenzoyl)-N-(6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl)benzamide in
10 20 ml of acetonitrile, 5 ml of 1N methanolic potassium hydroxide solution is added. The reaction mixture is heated under reflux conditions for 10 minutes, 1.5 ml of glacial acetic acid is added to it, then it is neutralized with 15 ml of 1M sodium hydrogen carbonate solution. The
15 precipitate is filtered off, the yellow crystalline material is recrystallized from the mixture of 5 ml of dimethylformamide and 40 ml of ethanol. After drying 1.3 g of the title compound is obtained, m.p.: 260 °C.
¹H-NMR (DMSO-d₆) 10.5 ppm (s, 1H), 8.92 (t, 1H), 8.4 (m, 2H), 7.66 (m, 3H), 7.35 (m, 5H), 7.05 (, 2H), 5.1 (d, 2H), 3.82 (m, 8H).

20

Example 2.

4-Methoxy-N-[6-(4-methylpiperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide

In the general formula (I) R¹ and R² stand for hydrogen atom, R³ for phenyl group, group a.) for 4-methylpiperazin-1-yl group, R⁶ for 4-methoxyphenyl group.
25

a.) 2-Nitro-5-(4-methylpiperazin-1-yl)benzoic acid:

The mixture of 10 g of 2-nitro-5-chlorobenzoic acid and 30 ml of *N*-methylpiperazine is stirred at 120 °C for 6 hours. To the reaction mixture 150 ml of ethyl acetate is added. The precipitated yellow crystalline material is filtered off, dissolved in 15 ml of water. The pH of the mixture is adjusted to 6 with acetic acid. The precipitated material is filtered off, washed with water and dried, to obtain 11.2 g of the title compound. Mp.: 212 °C.

¹H-NMR (DMSO-d₆) 7.89 ppm (d, 1H), 7.03-6.93 (m, 2H), 3.7-3.45 (m, 8H), 2.25 (s, 3H).

b.) 2-Amino-5-(4-methylpiperazin-1-yl)benzoic acid:

The mixture of 9 g of 2-nitro-5-(4-methylpiperazino)benzoic acid, 20 ml of cyclohexene and 3.5 g of Pd/C (10%) is heated under reflux conditions in 120 ml of ethanol for 6 hours. The hot reaction mixture is filtered through celite filter. The filtrate is evaporated to obtain 3.5 g of the title compound. M.p.: 212 °C

¹H-NMR (DMSO-d₆) 7.19 ppm (d, 1H), 7.06 (m, 1H), 6.69 (d, 1H), 2.9 (m, 4H), 2.43 (m, 4H), 2.22 (s, 3H).

c.) 5-(4-methylpiperazin-1-yl)isatoic anhydride:

To the mixture of 5.3 g of 2-amino-5-(4-methylpiperazino)benzoic acid in 30 ml of dioxane, under stirring and external cold water cooling 6 ml of diphosgene is added dropwise. The mixture is heated under reflux conditions for 4 hours. From the cold reaction mixture the solid material is filtered off, washed with 50 ml of ether. The product is stirred for 5 minutes in the mixture of 50 ml of methanol and 5 ml of triethylamine,

filtered off, washed with 30 ml of methanol. After drying 5.4 g of the title product is obtained, m.p.: 285 °C

¹H-NMR (DMSO-d₆) 7.81 ppm (m, 1H), 6.73 (m, 1H), 6.62 (m, 1H), 3.73-2.92 (m, 8H), 2.23 (s, 3H).

5

d.) 2-Amino-3-cyano-4-hydroxy-6-(4-methylpiperazin-1-yl)quinoline:

2 g of malonitrile is dissolved in 30 ml of dimethylformamide. To the solution, in several portions, 1.3 g of 60% oily dispersion of sodium hydride are added. To the clear solution 6.5 g of 5-(4-

10

methylpiperazino)isatoic acid anhydride is added and the mixture is stirred at room temperature for 10 hours. The reaction mixture is diluted with 70 ml of water and extracted with 2 X 30 ml of ethyl acetate. The aqueous phase is evaporated in vacuum, the solid residue is dissolved in 20 ml of water, the pH is adjusted to 6 with acetic acid. The precipitated material is filtered off, washed with water. After drying 5.2 g of the title compound is obtained, m.p.: 156 °C.

15

¹H-NMR (DMSO-d₆) 7.23 ppm (m, 1H), 7.12 (m, 1H), 7.03 (m, 1H), 3.65-2.83 (m, 8), 2.1 (s, 3H).

e.) 2-Amino-3-cyano-4-chloro-6-(4-methylpiperazin-1-yl)quinoline:

The mixture of 2 g of 2-amino-3-cyano-4-hydroxy-6-(4-methylpiperazino)quinoline and 4 ml of phosphoryl chloride is stirred at 120 °C for 4 hours. The cooled reaction mixture is poured onto 40 g of ice, the pH of the mixture is adjusted to 8 with 10% sodium hydroxide solution, and the precipitated material is filtered off. After drying 1.5 g of the title compound is obtained, m.p.: 189 °C.

¹H-NMR (DMSO-d₆) 7.69 ppm (m, 1H), 7.49 (m, 1H), 7.08 (m, 1H), 6.83 (s, 2H), 3.25-2.57 (m, 8H), 2.29 (s, 3H).

f.) 2-Amino-3-cyano-4-benzylamino-6-(4-methylpiperazin-1-yl)quinoline:

3 g of 2-amino-3-cyano-4-chloro-6-(4-methylpiperazino)quinoline and 6 ml of benzylamine are stirred at 125 °C for 3 hours. The reaction mixture is poured onto 30 ml of water. The precipitated material is filtered off, washed with 20 ml of water. After drying 2.3 g of the title compound is obtained, m.p.: 176 °C.

¹H-NMR (DMSO-d₆) 8.5 ppm (t, 1H), 7.5-7.15 (m, 8H), 5.85 (s, 2H), 5.04 (d, 2H), 3.65-3.12 (m, 8H), 2.23 (s, 3H).

g.) 4-Methoxy-N-(4-methoxybenzoyl)-N-[6-(4-methylpiperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide:

To the solution of 0.6 g of 2-amino-3-cyano-4-benzylamino-6-(4-methylpiperazino)quinoline in 2 ml of pyridine, 0.6 ml of 4-methoxybenzoyl chloride is added under stirring and cooling. The reaction mixture is stirred at 80 °C for 8 hours, and then poured onto 5 ml of ice-water. The precipitated material is filtered off, washed twice with 3 ml of water. After drying 0.63 g of the title compound is obtained, m.p.: 176 °C.

¹H-NMR (DMSO-d₆) 8.39 ppm (m, 1H), 7.95 (m, 2H), 7.47 (m, 5H), 7.32 (m, 5H), 7.14 (m, 4H), 5.1 (m, 2H), 3.82 (s, 3H), 3.52-2.98 (m, 8H), 2.25 (s, 3H).

5 h.) 4-Methoxy-N-[6-(4-methylpiperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide

To the solution of 2.3 g of 4-methoxy-N-(4-methoxybenzoyl)-N-(6-(4-methylpiperazino)-4-benzylamino-3-cyanoquinolin-2-yl)benzamide in 15 ml of acetonitrile, 4 ml of 1N methanolic potassium hydroxide solution is added. The reaction mixture is heated under reflux conditions for 10 minutes, 1 ml of glacial acetic acid is added to it, then it is neutralized with 12 ml of 1M sodium hydrogen carbonate solution. The precipitate is filtered off, the yellow crystalline material is recrystallized from the mixture of 15 ml of methanol and 35 ml of water. After drying 1.1 g of the title compound is obtained, m.p.: 173 °C.

¹H-NMR (DMSO-d₆) 10.53 ppm (m, 1H), 8.39 (m, 1H), 7.95 (m, 2H), 7.57 (m, 3H), 7.34 (m, 5H), 7.04 (m, 2H), 5.1 (m, 2H), 3.82 (s, 3H), 3.52-2.98 (m, 8H), 2.25 (s, 3H).

20 Example 3.

4-Methoxy-N-(6-dimethylamino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide

In the general formula (I) R¹ and R² stand for hydrogen atom, R³ for phenyl group, group a.) for dimethylamino group, R⁶ for 4-methoxyphenyl group.

25 a.) 2-Nitro-5-dimethylaminobenzoic acid:

The mixture of 5 g of 2-nitro-5-chlorobenzoic acid and 15 ml of 60% aqueous dimethylamine solution is stirred at 100 °C for 6 hours. The reaction mixture is evaporated, the residue dissolved in 15 ml of water. The pH of the mixture is adjusted to 6 with acetic acid. The precipitated yellow crystalline material is filtered off, washed with water and dried, to obtain 3.4 g of the title compound. Mp.: 189 °C.

¹H-NMR (DMSO-d₆) 7.78 ppm (d, 1H), 6.59 (m, 1H), 6.48 (m, 1H), 3.0 (s, 6H).

10 b.) 2-Amino-5-dimethylaminobenzoic acid:

The mixture of 2.1 g of 2-nitro-5-dimethylaminobenzoic acid, 7 ml of cyclohexene and 1.5 g of Pd/C (10%) is heated under reflux conditions in 60 ml of ethanol for 6 hours. The hot reaction mixture is filtered through celite filter. The filtrate is evaporated to obtain 1.1 g of the title compound. M.p.: 232 °C

¹H-NMR (DMSO-d₆) 7.01 ppm (m, 1H), 6.84 (m, 1H), 6.78 (m, 1H), 2.88 (s, 6H).

c.) 5-Dimethylaminoisatoic anhydride:

20 To the mixture of 8.9 g of 2-amino-5-dimethylaminobenzoic acid in 60 ml of dioxane, under stirring and external cold water cooling 10 ml of diposgene is added dropwise. The mixture is heated under reflux conditions for 4 hours. From the cold reaction mixture the solid material is filtered off, washed with 50 ml of ether. The product is stirred for 5 minutes in the mixture of 50 ml of methanol and 5 ml of triethylamine, filtered off, washed with 30 ml of methanol. After drying 7 g of the title product is obtained, m.p.: 258 °C

¹H-NMR (DMSO-d₆) 7.56 ppm (m, 1H), 7.42 (m, 1H), 7.13 (m, 1H), 2.97 (s, 6H).

d.) 2-Amino-3-cyano-4-hydroxy-6-dimethylaminoquinoline:

5 To the solution of 4 g of malonitrile in 50 ml of dimethylformamide in several portions 2.4 g of sodium hydride 60% oily dispersion is added. To the clear solution 8 g of 5-dimethylaminoisatoic anhydride is added and the mixture is stirred at room temperature for 10 hours. The mixture is diluted with 70 ml of water and extracted with 2 X 30 ml of ethyl acetate.

10 The aqueous phase is evaporated in vacuum, the solid residue is dissolved in 20 ml of water, the pH is adjusted to 6 with acetic acid. The precipitated material is filtered off, washed with water. After drying 6.5 g of the title compound is obtained, m.p.: 360 °C.

15 ¹H-NMR (DMSO-d₆) 7.43 ppm(m, 1H), 7.23(m, 1H), 7.11(m, 1H), 2.95(s, 6H).

e.) 2-Amino-3-cyano-4-chloro-6-dimethylaminoquinoline:

The mixture of 1.7 g of 2-amino-3-cyano-4-hydroxy-6-dimethylaminoquinoline and 3.4 ml of phosphoryl chloride is stirred at
20 120 °C for 4 hours. The cooled reaction mixture is poured onto 30 g of ice, the pH of the mixture is adjusted to 8 with 10% sodium hydroxide solution and the precipitated material is filtered off. After drying 1.5 g of the title compound is obtained, m.p.: 285 °C.

25 ¹H-NMR (DMSO-d₆) 7.43 ppm(mm, 1H), 7.21(m, 1H), 7.05(m, 1H), 6.75(s, 2H), 2.99(s, 6H).

f.) 2-Amino-3-cyano-4-benzylamino-6-dimethylaminoquinoline:

3 g of 2-amino-3-cyano-4-chloro-6-dimethylaminoquinoline and 6 ml of benzylamine are stirred at 125 °C for 3 hours. The reaction mixture is poured onto 30 ml of water. The precipitated material is filtered off,
5 washed with 20 ml of water. After drying 2.3 g of the title compound is obtained, m.p.: 265 °C.

¹H-NMR (DMSO-d₆) 8.55-8.45 ppm(m, 2H), 7.8(m, 1H), 7.5-7.23(m, 7H), 6.25(s, 2H), 5.08(d, 2H), 2.99(s, 6H).

10 g.) 4-Methoxy-N-(4-methoxybenzoyl)-N-(6-dimethylamino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide:

To the solution of 0.4 g of 2-amino-3-cyano-4-benzylamino-6-dimethylaminoquinoline in 2 ml of pyridine, 0.4 ml of 4-methoxybenzoyl chloride is added under stirring and cooling. The reaction mixture is
15 stirred at 80 °C for 8 hours, then poured onto 5 ml of ice-water. The precipitated material is filtered off, washed twice with 3 ml of water. After drying 0.53 g of the title compound is obtained, m.p.: 156 °C.

¹H-NMR (DMSO-d₆) 8.35 ppm(m, 1H), 7.9(m, 2H), 7.47(m, 5H), 7.3(m, 5H), 7.1(m, 4H), 5.12(m, 2H), 3.82(s, 3H), 3.0(s, 6H).

20

h.) 4-Methoxy-N-(6-dimethylamino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide

To the solution of 2.3 g of 4-methoxy-N-(4-methoxybenzoyl)-N-(6-dimethylamino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide in 20 ml
25 of acetonitrile, 5 ml of 1N methanolic potassium hydroxide solution is added. The reaction mixture is heated under reflux conditions for 10 minutes, 1.5 ml of glacial acetic acid is added to it, then it is neutralized with 15 ml of 1M sodium hydrogen carbonate solution. The precipitate is

filtered off, the yellow crystalline material is recrystallized from the mixture of 5ml of dimethylformamide and 40 ml of ethanol. After drying 1.3 g of the title compound is obtained, m.p.: 185 °C.

¹H-NMR (DMSO-d₆) 10.5 ppm(m, 1H), 8.35(m, 1H), 7.91(m, 2H),
5 7.53(m, 3H), 7.3(m, 5H), 7.02(m, 2H), 5.1(m, 2H), 3.85(s, 3H), 3.0(s, 6H).

Example 4

4-Methoxy-N-(6-dimethylamino-4-[2-furylmethylamino]-3-cyanoquinolin-2-yl)benzamide

10

In the general formula (I) R¹ and R² stand for hydrogen atom, R³ for 2-furylamino group, group a.) for dimethylamino group, R⁶ for 4-methoxyphenyl group.

15

a.) 2-Amino-3-cyano-4-[2-furylmethylamino]-6-dimethylaminoquinoline:

3 g of 2-amino-3-cyano-4-chloro-6-dimethylaminoquinoline and 6 ml of furfurylamine are stirred at 125 °C for 3 hours. The reaction mixture is poured onto 30 ml of water. The precipitated material is filtered off,
20 washed with 20 ml of water. After drying 2.05 g of the title compound is obtained, m.p.: 235 °C.

¹H-NMR (DMSO-d₆) 8.7 ppm(m, 1H), 7.6(m, 1H), 7.35-7.23(m, 3H), 6.8 (s, 2H), 6.4(m, 2H), 5.06(d, 2H), 2.96(s, 6H).

25 b.) 4-Methoxy-N-(4-methoxybenzoyl)-N-(6-dimethylamino-4-[2-furylmethylamino]-3-cyanoquinolin-2-yl)benzamide:

To the solution of 0.4 g of 2-amino-3-cyano-4-[2-furylmethylamino]-6-dimethylaminoquinoline in 2 ml of pyridine, 0.4 ml of 4-methoxybenzoyl

chloride is added under stirring and cooling. The reaction mixture is stirred at 80 °C for 8 hours, then poured onto 5 ml of ice-water. The precipitated material is filtered off, washed twice with 3 ml of water. After drying 0.5 g of the title compound is obtained, m.p.: 143 °C.

5 ¹H-NMR (DMSO-d₆) 8.35 ppm(m, 1H), 7.9-7.1(m, 14H), 5.12(m, 2H), 3.82(s, 6H), 3.0(s, 6H).

c.) 4-Methoxy-N-(6-dimethylamino-4-[2-furylmethylamino]-3-cyanoquinolin-2-yl)benzamide

10 To the solution of 2.3 g of 4-methoxy-N-(4-methoxybenzoyl)-N-(6-dimethylamino-4-[2-furylmethylamino]-3-cyanoquinolin-2-yl)benzamide in 20 ml of acetonitrile, 5 ml of 1N methanolic potassium hydroxide solution is added. The reaction mixture is heated under reflux conditions for 10 minutes, 1.5 ml of glacial acetic acid is added to it, then it is

15 neutralized with 15 ml of 1M sodium hydrogen carbonate solution. The precipitate is filtered off, the yellow crystalline material is recrystallized from the mixture of 5ml of dimethylformamide and 40 ml of ethanol. After drying 1.1 g of the title compound is obtained, m.p.: 195 °C.

20 ¹H-NMR (DMSO-d₆) 10.5 ppm(m, 1H), 8.25(t, 1H), 7.98(m, 2H), 7.63-7.03(m, 7H), 6.42 (d, 1H), 5.04(d, 2H), 3.85(s, 3H), 3.05(s, 6H).

Example 5

4-Methoxy-N-(6-dimethylamino-4-[2-thienylmethylamino]-3-cyanoquinolin-2-yl)benzamide

25

In the general formula (I) R¹ and R² stand for hydrogen atom, R³ for 2-thienylmethylamino group, group a.) for dimethylamino group, R⁶ for 4-methoxyphenyl group.

a.) 2-Amino-3-cyano-4-[2-thienylmethylamino]-6-dimethylaminoquinoline:

3 g of 2-amino-3-cyano-4-chloro-6-dimethylaminoquinoline and 6 ml of 2-
5 thienylmethylamine are stirred at 125 °C for 3 hours. The reaction mixture is
poured onto 30 ml of water. The precipitated material is filtered off, washed
with 20 ml of water. After drying 1.9 g of the title compound is obtained,
m.p.: 211 °C.

¹H-NMR (DMSO-d₆) 8.2 ppm(m, 1H), 7.46-6.95(m, 6H), 6.08(s, 2H), 5.18(d,
10 2H), 2.94(s, 6H).

b.) 4-Methoxy-N-(4-methoxybenzoyl)-N-(6-dimethylamino-4-[2-
thienylmethylamino]-3-cyanoquinolin-2-yl)benzamide:

15 To the solution of 0.4 g of 2-amino-3-cyano-4-[2-thienylmethylamino]-6-
dimethylaminoquinoline in 2 ml of pyridine, 0.4 ml of 4-methoxybenzoyl
chloride is added under stirring and cooling. The reaction mixture is stirred at
80 °C for 8 hours, then poured onto 5 ml of ice-water. The precipitated
material is filtered off, washed twice with 3 ml of water. After drying 0.43 g
20 of the title compound is obtained, m.p.: 171 °C.

¹H-NMR (DMSO-d₆) 8.35 ppm(m, 1H), 7.9-7.05(m, 14H), 5.12(m, 2H),
3.82(s, 6H), 3.0(s, 6H).

c.) 4-Methoxy-N-(6-dimethylamino-4-[2-thienylmethylamino]-3-
25 cyanoquinolin-2-yl)benzamide

To the solution of 2.3 g of 4-methoxy-N-(4-methoxybenzoyl)-N-(6-
dimethylamino-4-[2-thienylmethylamino]-3-cyanoquinolin-2-yl)benzamide

in 20 ml of acetonitrile, 5 ml of 1N methanolic potassium hydroxide solution is added. The reaction mixture is heated under reflux conditions for 10 minutes, 1.5 ml of glacial acetic acid is added to it, then it is neutralized with 15 ml of 1M sodium hydrogen carbonate solution. The precipitate is filtered
5 off, the yellow crystalline material is recrystallized from the mixture of 5ml of dimethylformamide and 40 ml of ethanol. After drying 1.15 g of the title compound is obtained, m.p.: 163 °C.

¹H-NMR (DMSO-d₆) 10.5 ppm(m, 1H), 8.3(t, 1H), 7.98(m, 2H), 7.63-6.96(m, 8H), 5.2(d, 2H), 3.85(s, 3H), 3.05(s, 6H).

10

Example 6

4-Methoxy-N-[6-(piperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide

15 In the general formula (I) R¹ and R² stand for hydrogen atom, R³ for phenyl group, group a.) for piperazino group, R⁶ for 4-methoxyphenyl group.

a.) 2-Nitro-5-(4-benzylpiperazin-1-yl)benzoic acid:

20 The mixture of 20 g of 2-nitro-5-chlorobenzoic acid and 50 ml of *N*-benzylpiperazine is stirred at 120 °C for 6 hours. To the reaction mixture 250 ml of ethyl acetate is added. The precipitated yellow crystalline material is filtered off, dissolved in 200 ml of water. The pH of the mixture is adjusted to 6 with acetic acid. The precipitated material is filtered off, washed with
25 water and dried, to obtain 30 g of the title compound. Mp.: 172 °C.

¹H-NMR (DMSO-d₆) 7.8-6.7 ppm (m, 8H), 3.5 (s, 2H), 3.5-2.8 (m, 8H).

b.) 2-Amino-5-(4-benzylpiperazin-1-yl)benzoic acid:

The mixture of 6 g of 2-nitro-5-(4-benzylpiperazin-1-yl)benzoic acid, 15 ml of cyclohexene and 3 g of Pd/C (10%) is heated under reflux conditions in
5 120 ml of ethanol for 6 hours. The hot reaction mixture is filtered through celite filter. The filtrate is evaporated to obtain 4.8 g of the title compound. M.p.: 242 °C.

¹H-NMR (DMSO-d₆) 7.5-6.8 ppm (m, 8H), 3.68 (s, 3H), 3.5-2.95 (m, 8H).

10 c.) 5-(4-benzylpiperazin-1-yl)isatoic anhydride:

To the mixture of 15 g of 2-amino-5-(4-benzylpiperazin-1-yl)benzoic acid in 90 ml of dioxane, under stirring and external cold water cooling 12.7 ml of diphosgene is added dropwise. The mixture is heated under reflux conditions
15 for 4 hours. From the cold reaction mixture the solid material is filtered off, washed with 120 ml of ether. The product is stirred for 5 minutes in the mixture of 100 ml of methanol and 10 ml of triethylamine, it is filtered off and washed with 50 ml of methanol. After drying 17 g of the title product is obtained, m.p.: 235 °C.

20 ¹H-NMR (DMSO-d₆) 7.68-7.1 ppm (m, 8H), 3.6 (s, 2H), 3.5-2.5(m, 8H).

d.) 2-Amino-3-cyano-4-hydroxy-6-(4-benzylpiperazin-1-yl)quinoline:

6.1 g of malonitrile is dissolved in 100 ml of dimethylformamide. To the
25 solution, in several portions, 3.6 g of 60% oily dispersion of sodium hydride are added. To the clear solution 18 g of 5-(4-benzylpiperazin-1-yl)isatoic anhydride is added and the mixture is stirred at room temperature for 10 hours. The reaction mixture is diluted with 100 ml of water and extracted

with 2 X 50 ml of ethyl acetate. The aqueous phase is evaporated in vacuum, the solid residue is dissolved in 50 ml of water, the pH is adjusted to 6 with acetic acid and refluxed for 5 hours. After cooling the precipitated material is filtered off, washed with water. After drying 14.3 g of the title compound is
5 obtained, m.p.: 291 °C.

¹H-NMR (DMSO-d₆) 7.7-6.5 ppm (m, 10H), 4.2 (s, 2H), 3.5-2.5 (m, 8H),

e.) 2-Amino-3-cyano-4-chloro-6-(4-benzylpiperazin-1-yl)quinoline:

10 The mixture of 14 g of 2-amino-3-cyano-4-hydroxy-6-(4-benzylpiperazin-1-yl)quinoline and 28 ml of phosphoryl chloride is stirred at 120 °C for 6 hours. The cooled reaction mixture is poured onto 500 g of ice, the pH of the mixture is adjusted to 8 with 10% sodium hydroxide solution, and the precipitated material is filtered off. After drying 14.5 g of the title compound
15 is obtained, m.p.: 206 °C.

¹H-NMR (DMSO-d₆) 7.7-7.14 ppm (m, 8H), 6.9 (s, 2H), 3.7 (s, 2H), 3.5-2.5 (m, 8H).

f.) 2-Amino-3-cyano-4-benzylamino-6-(4-benzylpiperazin-1-yl)quinoline:

20

14 g of 2-amino-3-cyano-4-chloro-6-(4-benzylpiperazin-1-yl)quinoline and 28 ml of benzylamine are stirred at 125 °C for 4 hours. The reaction mixture is poured onto 100 ml of water. The precipitated material is filtered off, washed with 2 x 50 ml of water. After drying 8 g of the title compound is
25 obtained, m.p.: 202 °C.

¹H-NMR (DMSO-d₆) 8.1 ppm (m, 1H), 7.5-7.2 (m, 13H), 5.8 (s, 2H), 5.0 (d, 2H), 3.54 (s, 2H), 3.5-2.5 (m, 8H).

g.) 4-Methoxy-N-(4-methoxybenzoyl)-N-(6-(4-benzylpiperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl)benzamide:

To the solution of 0.9 g of 2-amino-3-cyano-4-benzylamino-6-(4-benzylpiperazin-1-yl)quinoline in 5 ml of ethylacetate containing 0.3 ml of triethylamine, 0.5 ml of 4-methoxybenzoyl chloride is added under stirring and cooling. The reaction mixture is stirred at 80 °C for 8 hours, then poured onto 10 ml of ice-water. The precipitated material is filtered off, washed twice with 3 ml of water. After drying 0.53 g of the title compound is obtained, m.p.: 157 °C.

¹H-NMR (DMSO-d₆) 8.92 ppm (t, 1H), 8.32 (m, 4H), 7.61 (m, 3H), 7.38 (m, 5H), 7.12 (m, 4H), 5.1 (d, 2H), 3.82 (s, 6H), 3.56 (s, 2H), 3.5-2.5 (m, 8H).

h.) 4-Methoxy-N-[(6-(4-benzylpiperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl)]benzamide

To the solution of 2.0 g of 4-methoxy-N-(4-methoxybenzoyl)-N-(6-(4-benzylpiperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl)benzamide in 20 ml of acetonitrile, 4 ml of 1N methanolic potassium hydroxide solution is added. The reaction mixture is heated under reflux conditions for 10 minutes, 1.5 ml of glacial acetic acid is added to it, then it is neutralized with 15 ml of 1M sodium hydrogen carbonate solution. The precipitate is filtered off, the yellow crystalline material is recrystallized from the mixture of 5 ml of dimethylformamide and 40 ml of ethanol. After drying 1.3 g of the title compound is obtained, m.p.: 260 °C.

¹H-NMR (DMSO-d₆) 10.5 ppm (s, 1H), 8.92 (t, 1H), 7.97-7.01 (m, 17H), 5.1 (d, 2H), 3.82 (s, 3H), 3.56 (s, 2H), 3.5-2.5 (m, 8H).

i.) 4-Methoxy-N-[(6-(piperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide

1 g of 4-methoxy-N-[(6-(4-benzylpiperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide was dissolved in dimethylformamide and water, containing 0.5 ml of acetic acid and was hydrogenated in the presence of 50 mg of Pd/C (10%) for 4 hours at 45 °C. After filtration of the catalyst and evaporation of the solvent the crude product was purified by chromatography to give 0.65 g of the title compound, mp: 145 °C.

¹H-NMR (DMSO-d₆) 10.5 ppm (s, 1H), 8.48 (m, 1H), 7.94 (m, 2H), 7.6-7.35 (m, 2H), 7.33 (s, 5H), 7.24 (m, 1H), 7.02 (m, 2H), 5.08 (d, 2H), 3.83 (s, 3H), 3.22 (m, 4H), 2.86 (m, 4H).

Example 7

N-[6-amino-4-(benzylamino)-3-cyanoquinolin-2-yl]-4-methoxybenzamide

In the general formula (I) R¹ and R² stand for hydrogen atom, R³ for phenyl group, NR⁴R⁵ stands for NH₂, R⁶ for 4-methoxyphenyl group.

a.) 5-Nitroisatoic anhydride:

To the mixture of 37 g of 2-amino-5-nitrobenzoic acid in 500 ml of dioxane, under stirring 24.5 ml of diphosgene was added dropwise. The mixture was heated under reflux conditions for 6 hours then it was evaporated to dryness. The residue was suspended in 100 ml of diethyl ether and filtered off to give 41.4 g of the title product as HCl salt, m.p.: 256-259 °C. LC-MS: MH⁺ 209; Ret. time: 5.00 min.

¹H-NMR (DMSO-*d*₆) 8.54 (d, 1H), 8.46 (dd, 1H), 7.37 (d, 1H) ppm.

b,) 2-Amino-3-cyano-4-hydroxy-6-nitroquinoline:

- 5 To the solution of 47.25 g of 5-nitroisatoic anhydride in 230 ml of DMF 15 g of malonitrile and 63.3 ml of triethylamine were added and the reaction mixture was stirred at 60 °C for 2 hours. The solvent was evaporated at reduced pressure and the residue was mixed with 570 ml of acetonitrile and 114 ml of concd. HCl and the solution was stirred at room temperature
10 overnight. The precipitate was then filtered off, washed with water and ethanol to give 49.7 g of product, m.p.: >360 °C. LC-MS: MH⁺ 231; Ret. time: 4.78 min.

¹H-NMR (DMSO-*d*₆) 8.64 (d, 1H), 8.36 (dd, 1H), 7.6 (s, 2H), 7.55 (d, 1H) ppm.

15

c,) 2-Amino-3-cyano-4-chloro-6-nitroquinoline:

- The stirred mixture of 48.5 g of 2-amino-3-cyano-4-hydroxy-6-nitroquinoline and 550 ml of phosphoryl chloride was refluxed for 4 hours. The reaction
20 mixture was concentrated to half of its volume and the residue was poured onto 1500 g of ice. The yellow precipitate was filtered off, washed with water to give 60.5 g of solid. 25 g of this solid was stirred at room temperature in 500 ml of 0.5 N HCl for 6 hours, then the precipitate was filtered off, washed with water to give 18.5 g of product, m.p.: >360 °C. LC-MS: MH⁺ 249; Ret.
25 time: 5.94 min.

¹H-NMR (DMSO-*d*₆) 8.73 (d, 1H), 8.48 (dd, 1H), 7.92 (d, 1H) ppm.

d,) 2-Amino-3-cyano-4-benzylamino-6-nitroquinoline:

A mixture of 7 g of 2-amino-3-cyano-4-chloro-6-nitroquinoline and 30 ml of benzylamine was stirred at 55 °C for 1.5 hours. The reaction mixture is
5 poured onto 30 ml of water. The precipitated material is filtered off, washed with water to give 7 g of the title compound, m.p.: 280-283 °C. LC-MS: MH⁺ 2320; Ret. time: 5.19 min.

¹H-NMR (DMSO-d₆): 9.28 (d, 1H), 8.90 (t, 1H), 8.24 (dd, 1H), 7.3 (m, 5H), 6.98 (s, 2H), 5.04 (d, 2H) ppm.

10

e,) 4-Methoxy-N-(4-methoxybenzoyl)-N-(4-benzylamino-3-cyano-6-nitroquinolin-2-yl)benzamide:

A suspension of 3.5 g of 2-amino-3-cyano-4-benzylamino-6-nitroquinoline in
15 50 ml of dry pyridine was refluxed with 5.6 g of 4-methoxybenzoyl chloride for 3.5 hours. The solvent was evaporated in reduced pressure and the residue was suspended in 30 ml of a saturated solution of Na₂CO₃ in water. The suspension was extracted with 3 x 25 ml of CH₂Cl₂. The combined organic extract was evaporated to dryness, the residue was dissolved in diethyl ether
20 and the solution was kept in a refrigerator for a night. The precipitate was filtered off, washed with diethyl ether to give 6.25 g of the title compound, m.p.: 145-148 °C. LC-MS: MH⁺ 588; Ret. time: 7.00 min.

f,) N-[(4-Benzylamino-3-cyano-6-nitroquinolin-2-yl)-4-methoxy-benzamide

25

A suspension of 6.2 g of N-(4-methoxybenzoyl)-N-(4-benzylamino-3-cyano-6-nitroquinolin-2-yl)-4-methoxybenzamide in 75 ml of acetonitrile was refluxed with 25.2 ml of 1N methanolic potassium hydroxide solution for 6

min. 4.4 ml of glacial acetic acid was dropped to the solution while hot, cooled and neutralized with 56.3 ml of 1M aqueous NaHCO₃ solution. The precipitate was filtered off, washed with water to give 4.1 g of title compound, m.p.: 264-266 °C.

- 5 ¹H-NMR (DMSO-d₆) 10.9 (s, 1H), 9.55 (d, 1H), 9.28 (t, 1H), 8.77 (d, 1H), 8.48 (dd, 1H), 8.00 (d, 2H), 7.90 (d, 1H), 7.4 (m, 4H), 7.29 (m, 1H), 7.05 (d, 2H), 5.12 (d, 2H), 3.84 (s, 3H) ppm.

g,) N-[6-amino-4-(benzylamino)-3-cyanoquinolin-2-yl]-4-methoxybenzamide

10

A mixture of 320 ml of ethanol, 80 ml of water, 200 ml of THF, 7.6 g of Fe-powder, and 1 ml of concd. HCl was refluxed for 10 min. 9 g of N-[(4-benzylamino-3-cyano-6-nitroquinolin-2-yl)-4-methoxy-benzamide was then added and the reaction mixture was intensively refluxed for 2 hours and it

- 15 was cooled to 35 °C. The precipitate was filtered off, washed with a 1:1 mixture of CH₂Cl₂ and ethanol. The combined organic solution was filtered on charcoal and evaporated to dryness. The residue was suspended in a mixture of 50 ml of water and 10 ml of ethanol, the solid material was filtered off, washed with water to give 6.65 g of the title compound, mp: 228-230 °C.

- 20 LC-MS: MH⁺ 424; Ret. time: 5.33 min.

¹H-NMR (DMSO-d₆) 10.44 (s, 1H), 8.0 (s+d, 3H), 7.50 (d, 1H), 7.3-7.1 (m, 7H), 7.03 (d, 2H), 5.55 (s, 2H), 5.04 (d, 2H), 3.83 (s, 3H) ppm.

Example 8

25

N-{6-amino-4-[(2-thienylmethyl)amino)]-3-cyanoquinolin-2-yl}-4-methoxybenzamide

In the general formula (I) R^1 and R^2 stand for hydrogen atom, R^3 for 2-thienyl group, NR^4R^5 stands for NH_2 , R^6 for 4-methoxyphenyl group.

a,) 2-Amino-3-cyano-4-(2-thienylmethyl)amino-6-nitroquinoline:

5

Applying the same procedure as given under Example 7d with the modification that instead of benzylamine, (2-thienylmethyl)amine was used to give 7.1 g of the title compound, m.p.: 277-280 °C. LC-MS: MH^+ 326; Ret. time: 5.25 min.

10

b,) N-(4-Methoxybenzoyl)-N-[3-cyano-6-nitro-4-(2-thienylmethyl)-aminoquinolin-2-yl]-4-methoxybenzamide:

15

Started the reaction from 2-amino-3-cyano-4-(2-thienylmethyl)amino-6-nitroquinoline (3.6 g) and using the procedure as given for Example 7e, 6.3 g of the title compound was prepared, m.p.: 174-177 °C. LC-MS: MH^+ 595; Ret. time: 7.16 min.

20

c,) N-[3-Cyano-6-nitro-4-(2-thienylmethyl)aminoquinolin-2-yl]-4-methoxybenzamide

25

Started the reaction from N-(4-methoxybenzoyl)-N-[3-cyano-6-nitro 4-(2-thienylmethyl)amino]quinolin-2-yl)-4-methoxybenzamide (6.2 g) and using the procedure as given for Example 7f, 4.3 g of the title compound was prepared, m.p.: 217-220 °C. LC-MS: MH^+ 460; Ret. time: 6.57 min.

1H -NMR ($DMSO-d_6$): 11.0 (s, 1H), 9.50 (s, 1H), 9.29 (s, 1H), 8.48 (dd, 1H), 8.02 (d, 2H), 7.90 (d, 1H), 7.48 (dd, 1H), 7.21 (d, 1H), 7.0 (m, 3H), 5.27 (s, 2H), 3.85 (s, 3H) ppm

d,) *N*-{6-amino-4-[(2-thienylmethyl)amino]-3-cyanoquinolin-2-yl}-4-methoxybenzamide

Started the reaction from *N*-[4-(2-thienylmethyl)amino-3-cyano-6-

5 nitroquinolin-2-yl]-4-methoxybenzamide (10 g) and using the procedure as given for Example 7g, 9.3 g of the title compound was prepared, mp: 200-203 °C. LC-MS: MH⁺ 430; Ret. time: 5.52 min.

¹H-NMR (DMSO-d₆) 10.48 (s, 1H), 7.98 (s+d, 3H), 7.50 (d, 1H), 7.41 (dd, 1H), 7.21 (s, 1H), 7.16 (dd, 1H), 7.11 (d, 1H), 7.04 (d, 2H), 6.98 (dd, 1H),
10 5.45 (s, 2H), 5.18 (d, 2H), 3.84 (s, 3H) ppm

Example 9

15 *N*-{4-(benzylamino)-3-cyano-6-(methylamino)quinolin-2-yl}-4-methoxybenzamide

In the general formula (I) R¹ and R² stand for hydrogen atom, R³ for phenyl group, R⁴ stands for Me, R⁵ stands for H and R⁶ for 4-methoxyphenyl group.

20 A suspension of 1 g of *N*-{4-(benzylamino)-3-cyano-6-aminoquinolin-2-yl}-4-methoxybenzamide and 0.65 g of paraformaldehyde in a mixture of 48 ml of ethanol and 48 ml of CH₂Cl₂ was refluxed with 0.5 ml of 54% HBF₄ solution in diethyl ether for 1.5 hours. After addition of 0.3 g of NaBH₄ the reflux was continued for 1.5 hours followed by addition of a further amount
25 of 0.3 g of NaBH₄ and reflux for 2 hours. After repeated addition of 0.25 ml of 54% HBF₄ solution in diethyl ether and 0.3 g of NaBH₄ the reflux was continued for additional 1.5 hours. The reaction mixture was filtered while hot, the solid was washed with a 1:1 mixture of CH₂Cl₂ and ethanol. The combined organic solution was concentrated and the residue was

chromatographed on silica gel with a 50:1 mixture of CHCl₃ and ethyl acetate to give the crude product. It was recrystallized from a 2:1 mixture of ethanol and DMF to give 0.6 g of title compound, m.p.: 237-240 °C. LC-MS: MH⁺ 438; Ret. time: 5.76 min.

- 5 ¹H-NMR (DMSO-d₆) 10.43 (s, 1H), 8.18 (t, 1H), 7.94 (d, 2H), 7.50 (d, 1H), 7.3-7.0 (m, 9H), 6.24 (m, 1H), 5.08 (d, 2H), 3.83 (s, 3H), 2.83 (d, 3H) ppm.

Example 10

- 10 N-{3-Cyano-6-(formylamino)-4-[(2-thienylmethyl)amino]quinolin-2-yl}-4-methoxybenzamide

- 15 In the general formula (I) R¹ and R² stand for hydrogen atom, R³ for 2-thienyl group, R⁴ stands for Me, R⁵ stands for CHO and R⁶ for 4-methoxyphenyl group.

- 20 A suspension of 0.32 g of N-{6-amino-4-[(2-thienylmethyl)amino]-3-cyanoquinolin-2-yl}-4-methoxybenzamide was kept in 60 ml of methyl formate at 100 °C in a closed apparatus (internal pressure: 10 bar) for 7 hours. After cooling the solvent was evaporated and the residue was recrystallized from CH₂Cl₂/MeOH to give 0.22 g of title compound, m.p.: 223-226 °C. LC-MS: MH⁺ 458; Ret. time: 5.71 min.

- 25 Example 11

{4-(Benzylamino)-3-cyano-2-[(4-methoxybenzoyl)amino]quinolin-6-yl} sulfamic acid

In the general formula (I) R^1 and R^2 stand for hydrogen atom, R^3 for phenyl group, R^4 stands for H, R^5 stands for SO_2OH and R^6 for 4-methoxyphenyl group.

- 5 To a solution of 5.2 g of $Na_2S_2O_4$ (purity: 85%) in 160 ml of water and 200 ml of ethanol was added 20 ml of aqueous 1N NaOH solution. The solution was heat up to boiling then 2.27 g of *N*-[(4-benzylamino-3-cyano-6-nitroquinolin-2-yl]-4-methoxybenzamide was added and refluxing was continued for 2 hours. The reaction mixture let stand at room temperature
- 10 overnight then it was concentrated to half of its volume. The residue was made alkaline (pH=8) by addition of 1N NaOH solution and was extracted with CH_2Cl_2 . The aqueous solution was acidified to pH=5 by addition of concd. HCl solution and the precipitate was filtered off. The solid was chromatographed on silica gel eluted first by a mixture of ethyl
- 15 acetate/methanol/25% ammonia = 220/30/2, then 200/80/2 to get 0.5 g of title compound as ammonium salt, m.p.: 220-222 °C. LC-MS: MH^+ 504; Ret. time: 5.56 min.
- 1H -NMR ($DMSO-d_6$) 10.48 (s, 1H), 8.21 (s, 1H), 8.09 (t, 1H), 7.95 (d, 2H), 7.70 (s, 1H), 7.62 (d, 1H), 7.56 (d, 1H), 7.3 (m, 4H), 7.25 (m, 1H), 7.03 (d,
- 20 2H), 5.05 (d, 2H), 3.83 (s, 3H) ppm

Example 12

- {4-(Benzylamino)-3-cyano-2-[(4-methoxybenzoyl)amino]quinolin-6-yl}methylsulfamic acid
- 25

In the general formula (I) R^1 and R^2 stand for hydrogen atom, R^3 for phenyl group, R^4 stands for Me, R^5 stands for SO_2OH and R^6 for 4-methoxyphenyl group.

- 5 A solution of 110 mg of *N*-{4-(benzylamino)-3-cyano-6-(methylamino)quinolin-2-yl}-4-methoxybenzamide in 10 ml of pyridine was stirred at room temperature with 0.2 ml of DBU and 150 mg of pyridinium- SO_3 complex for 2 hours. The reaction mixture was concentrated to dryness, the residue was chromatographed on silica gel using a mixture of ethyl
10 acetate/methanol/25% ammonia = 200/80/2 as eluent to give 10 mg of title compound as ammonium salt. LC-MS: MH^+ 518; Ret. time: 6.22 min.

Example 13

- 15 *N*-{4-(Benzylamino)-3-cyano-6-[formyl(methyl)amino]quinolin-2-yl}-4-methoxybenzamide

In the general formula (I) R^1 and R^2 stand for hydrogen atom, R^3 for phenyl group, R^4 stands for Me, R^5 stands for CHO and R^6 for 4-methoxyphenyl
20 group.

- A suspension of 110 mg of *N*-{4-(benzylamino)-3-cyano-6-(methylamino)quinolin-2-yl}-4-methoxybenzamide was refluxed in 10 ml of ethyl formate for 24 hours. After cooling the precipitated crystals were
25 filtered off, washed with ethyl formate and ethanol to give 30 mg of title compound, m.p.: 237-240 °C. LC-MS: MH^+ 465; Ret. time: 6.11 min.

Example 14

4-Methoxy-N-[6-(4-formylpiperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide

5

In the general formula (I) R¹ and R² stand for hydrogen atom, R³ for phenyl group, group a.) for 4-formylpiperazino group, R⁶ for 4-methoxyphenyl group.

- 10 A solution of 120 mg of 4-methoxy-N-[6-(piperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide in 5 ml of ethyl formate was refluxed for 2 hours. After cooling the solvent was evaporated and the residue was recrystallised from methanol to give 65 mg of the title compound. mp: 243°C
- 15 ¹H-NMR (DMSO-d₆) 10.6 ppm (s, 1H), 8.48 (m, 1H), 8.1 (s, 1H), 7.94 (m, 2H), 7.6-7.1 (m, 8H), 7.05 (m, 2H), 5.1 (d, 2H), 3.82 (s, 3H), 3.7-3.2 (m, 8H).

Example 15

4-[2-(Benzoylamino)-4-benzylamino)-3-cyanoquinolin-6-yl]piperazine-1-sulfonic acid

20

In the general formula (I) R¹ and R² stand for hydrogen atom, R³ for phenyl group, group a.) for 4-sulfonylpiperazino group, R⁶ for 4-methoxyphenyl group.


25

A solution of 50 mg of 4-methoxy-N-[6-(piperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide in 0.5 ml pyridine and pyridinium-SO₃ complex was refluxed for 2 hours and working up according to a procedure

published in the literature (G.F. Smith and D.A. Taylor, Tetrahedron, 29, 669, 1973).





LC-MS: MH^+ 572; Ret. time: 5.9 min.

















- 5 Structure and physical characteristics of further compounds of the general formula (I), wherein R^1 and R^2 stand for hydrogen atom, X stands for $-NH-$ group and n represents 1, are shown in Table I

































10



Table I

No	R^3	R^4	R^5	R^6	Mp (°C)	LC-MS MH^+ /Ret time (min)	Process of example
16		Me	Me		211		4
17		Me	Me		208		4

18		Me	Me		198		4
19		Me	Me		176		4
20		Me	Me		152		4
21		Me	Me		163		4
22		Me	Me		172		4
23		Me	Me		158		4
24		Me	Me		170		4
25		Me	Me		171		4

26		Me	Me		165		4
27		Me	Me		148		4
28		H	H		235	424/5.65	7
29		H	H		234	470/6.12	7
30		H	H		222	444/5.54	7
31		H	Me		160	444/5.74	9
32		H			217	517/5.86	11

33		H			257	509/5.70	11
34		H			208	523/5.97	11
35		H	CHO			465/7.53	10
36		H	CHO			452/5.69	10
37		H	CHO		247	471/5.75	10
38		Me				523/6.14	12

39		Me	CHO		248	471/5.86	13
----	---	----	-----	---	-----	----------	----

Example 40

Tablets of the following composition are prepared by known methods:

5	Active ingredient:	25 mg
	Lactose	50 mg
	Avicel	21 mg
	Crospovidone	3 mg
	Magnesium stearate	1 mg

10

Biology

Methods

Human adenosine A₃ receptor binding

Preparing membrane suspension: ovarium cells of Chinese hamster
 15 expressing cloned human A₃ receptors (further: CHO-hA₃) are appropriately
 cultured and maintained. Achieving confluent cell layer, the medium is
 removed from the cells by washing them with 37 °C PBS, then the cell are
 suspended in ice cold PBS, centrifuged (1000 x g 10 min) (Sigma 3K30) and
 homogenized using teflon homogenizer (B.Braun Potter S) at 1500/min
 20 rotation speed, for 15 sec. in the following buffer: 50 mM Tris, 10 mM
 MgCl₂, 1 mM EDTA, pH 8.0. The suspension is centrifuged (43.000 g, 10
 min). The pellet is suspended in the above buffer, protein concentration 0.1
 mg/ml (Bradford method). Aliquots of the membrane preparation are stored
 at -80 °C.

Binding protocol: incubate CHO-hA₃ membrane preparation (2 µg protein content) in incubation buffer (50 mM Tris, 10 mM MgCl₂, 1 mM EDTA, 3 U/mL adenosine deaminase, pH 8.0), in the presence of 0.5 nM [¹²⁵I]AB-MECA (*p*-amino-3-iodo-benzyl-5'-*N*-methylcarboxamido-adenosine) (100.000 cpm) and 100 µM R-PIA (*N*⁶-[L-2-phenylisopropyl]adenosine) to define non-specific binding of test compound in a total volume of 50 µL for 1 hr at room temperature. Filter over Whatman GF/B glass fibre filters (presoaked in 0.5% polyethylenimine for 3 hours), wash 4x with 1 mL ice-cold 50 mM Tris, 10 mM MgCl₂, 1 mM EDTA (pH 8.0) on 96-well Brandel Cell Harvester. Detection of activity: in gamma-counter (1470 Wizard, Wallac). Inhibition [%] = 100-((activity in the presence of test compound - non-specific activity)/(total activity - non-specific activity))*100

Human adenosine A₁ receptor binding

- 15 Preparing membrane suspension: ovarium cells of Chinese hamster expressing cloned human A₁ receptors (further: CHO-hA₁) are appropriately cultured and maintained. Achieving confluent cell layer, the medium is removed from the cells by washing them with 37 °C PBS, then the cell are suspended in ice cold PBS, centrifuged (1000 x g 10 min) (Sigma 3K30) and
- 20 homogenized using teflon homogenizer (B.Braun Potter S) at 1500/min rotation speed, for 15 sec. in the following buffer: 50 mM Tris, 10 mM HCl, pH 7.4. The suspension is centrifuged (43.000 g, 10 min). The pellet is suspended in the above buffer, protein concentration 5 mg/ml (Bradford method). Aliquots of the membrane preparation are stored at -80 °C.
- 25 Binding protocol: incubate CHO-hA₁ membrane preparation (50 µg protein content) in incubation buffer (50 mM Tris, 3 U/mL adenosine deaminase, pH 7.4), 10 nM [³H]CCPA (2-chloro-*N*⁶-cyclopenthy-adenosine) (80.000 dpm) and 10 µM R-PIA (*N*⁶-[L-2-phenylisopropyl]adenosine) to define the non-

specific binding or test compound in a total volume of 100 μ L for 3 hr at room temperature. Filter over Whatman GF/B glass fibre filters (presoaked in 0.5% polyethylenimine for 3 hours), wash 4x with 1 mL ice-cold 50 mM Tris (pH 7.4) on 96-well Brandel Cell Harvester. Detection of activity: in the presence of 200 μ L of HiSafe-3 cocktail in beta-counter (1450 Microbeta, Wallac). Inhibition [%] = $100 - ((\text{activity in the presence of test compound} - \text{non-specific activity}) / (\text{total activity} - \text{non-specific activity})) * 100$

Human adenosine A_{2a} receptor binding

Binding protocol: Incubate 7 μ g of membranes (human A_{2a} adenosine receptors transfected into HEK-293 cells, source: Receptor Biology, Inc.), buffer (50 mM Tris-HCl, 10 mM MgCl₂, 1 mM EDTA, 2 U/mL adenosine deaminase, pH 7.4), 20 nM [³H]CGS-21680 (2-[p-(2-carbonylethyl)phenylethylamino]-5'-N-ethylcarboxamido-adenosine) (200.000 dpm) and 50 μ M NECA (5'-N-ethylcarboxamido-adenosine) to define the non-specific binding of test compound, in a total volume of 100 μ L for 90 min at room temperature. Filter in vacuum over Whatman GF/B glass fibre filters (presoaked for 3 hours in 0.5% polyethylenimine), wash 4x with 1 mL ice-cold 50 mM Tris, 10 mM MgCl₂, 1 mM EDTA, 0.9 % NaCl, pH 7.4) on 96-well Brandel Cell Harvester. Detection of activity: in beta-counter (1450 Microbeta, Wallac) in the presence of 200 μ L of HiSafe-3 cocktail. Inhibition [%] = $100 - ((\text{activity in the presence of test compound} - \text{non-specific activity}) / (\text{total activity} - \text{non-specific activity})) * 100$.

Human adenosine A_{2b} receptor binding

Binding protocol: incubate 20.8 μ g of membranes (human A_{2b} adenosine receptors transfected into HEK-293 cells, source: Receptor Biology, Inc.), buffer (50 mM Tris-HCl, 10 mM MgCl₂, 1 mM EDTA, 0.1 mM benzamidine, 2 U/mL adenosine deaminase, pH 6.5), 32.4 nM [³H]DPCPX (8-cyclopentyl-1,3-dipropylxanthine) (800.000 dpm) and 100 μ M NECA (5'-

N-ethylcarboxamido-adenosine) to define non-specific binding or test compound in a total volume of 100 μ L for 30 min at room temperature. Filter under 25 Hgmm vacuum over Whatman GF/C glass fibre filters (presoaked in 0.5% polyethylenimine for 3 hours), wash 4x with 1 mL ice-cold 50 mM Tris-HCl (pH 6.5) on 96-well Brandel Cell Harvester. Detection of activity: in the presence of 200 μ L of HiSafe-3 cocktail in beta-counter (1450 Microbeta, Wallac). Inhibition [%] = $100 - ((\text{activity in the presence of test compound} - \text{non-specific activity}) / (\text{total activity} - \text{non-specific activity})) * 100$

10 Results

We consider the compounds as biologically active ones if they inhibit the binding of the radioligand on human adenosine A_3 receptors with an activity above 80 % at 1 μ M in our experimental conditions.

The dissociation constant (K_d) of [125 I]AB-MECA on CHO-h A_3 membrane preparation is determined by isotope saturation studies with the help of Scatchard analysis (G. Scatchard, Ann. N. Y. Acad. Sci. 51:660, 1949). The IC_{50} is converted to an affinity constant (K_i) by application of the Cheng-Prusoff equation (Y. J. Cheng and W. H. Prusoff, Biochem. Pharmacol. 22:3099, 1973).

20 A number of the compounds of the general formula (I) displayed remarkable biological effects. The most active compounds of the general formula (I) were those defined in claims 2-4. Especially advantageous are the compounds given in the Examples, their K_i values are in the range of 0.5 nM and 900 nM, preferably 0.5 nM and 700 nM. K_i values of the most
25 advantageous compounds are in the range of 0.5 nM 18 nM, most preferably 0.5 and 15 nM.

The compounds possess good bioavailability and a selectivity of at least 3 order of magnitude, in respect to the human adenosine A₁, A_{2a} and A_{2b} receptor subtypes.

Further, the duration of their action at intravenous and oral
5 administration is long, their ED₅₀ values are low, their toxicological and side-effect profiles are advantageous.

These above data are favourable for the therapeutic application of the compounds of the general formula (I).

Claims

1. Compounds of the general formula (I), wherein
- 5 R^1 stands for hydrogen atom or a straight or branched C_{1-4} alkyl group;
 R^2 stands for hydrogen atom or a straight or branched C_{1-4} alkyl group;
 R^3 stands for hydrogen atom, or a straight or branched C_{1-4} alkyl group,
 C_{3-6} cycloalkyl group, a phenyl, thienyl, or furyl group, optionally
substituted with one or more straight or branched C_{1-4} alkyl group,
10 straight or branched C_{1-4} alkoxy group, or halogen atom; a six- or five-
membered heteroaromatic ring containing one, two or three nitrogen
atoms, or a five-membered heteroaromatic ring containing one nitrogen
atom and one oxygen atom, or one nitrogen atom and one sulphur
atom, optionally substituted with one or more straight or branched
15 C_{1-4} alkyl group, straight or branched C_{1-4} alkoxy group, or halogen
atom;
- R^4 and R^5 independently stand for hydrogen atom, C_{3-6} cycloalkyl group,
straight or branched C_{1-4} alkyl group - optionally containing an amino
group, or an amino group substituted with one or two straight or
20 branched C_{1-4} alkyl group, a hydroxy group, a carboxy group, or an
alkoxy group substituted with a straight or branched C_{1-4} alkyl group -;
or
- R^4 stands for hydrogen atom or a straight or branched C_{1-4} alkyl group or a
benzyl group, and
- 25 R^5 stands for hydrogen atom, $-SO_2OH$ group or a straight or branched
 C_{1-4} acyl group, or

- R^4 and R^5 , together with the nitrogen atom, form a group of the general formula a.), wherein R^7 and R^8 independently stand for hydrogen atom, straight or branched C_{1-4} alkyl group or C_{3-6} cycloalkyl group;
- R^6 stands for hydrogen atom or straight or branched C_{1-4} alkyl group, phenyl, benzyl, thienyl, or furyl group, optionally substituted with methylenedioxy group, or with one or more straight or branched C_{1-4} alkyl group, straight or branched C_{1-4} alkoxy group, hydroxy group, trifluoromethyl group, cyano group or halogen atom; or a six- or five-membered heteroaromatic ring containing one, two or three nitrogen atoms, or one nitrogen atom and one oxygen atom, or one nitrogen atom and one sulphur atom, optionally substituted with one or more straight or branched C_{1-4} alkyl group, straight or branched C_{1-4} alkoxy group or halogen atom;
- X stands for $-CH_2-$ group, $-NH-$ group, $-NR^9-$ group, or sulphur atom, oxygen atom, sulpho group or sulphoxy group, wherein R^9 stands for straight or branched C_{1-4} alkyl group or C_{3-6} cycloalkyl group;
- Z stands for oxygen atom sulphur atom, $-CHR^{10}-$ group or $-NR^{11}-$ group, wherein R^{10} stands for hydrogen atom, straight or branched C_{1-4} alkyl group, or C_{3-6} cycloalkyl group and R^{11} stands for hydrogen atom, straight or branched C_{1-4} alkyl group, C_{3-6} cycloalkyl group, $-SO_2OH$ group or a straight or branched C_{1-4} acyl group ;
- n represents zero, 1 or 2;
- m represents 1, 2, or 3;
- o represents 1, 2, or 3;
- p represents zero or 1;
- r represents zero or 1,
- and their salts, solvates, isomers (tautomers, desmotrops, optically active isomers) as well as the salts and solvates.

2. Compounds of the general formula (I) according to claim 1., wherein
- R¹ stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group;
- R² stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group;
- 5 R³ stands for hydrogen atom, or a straight or branched C₁₋₄ alkyl group, C₃₋₆ cycloalkyl group, a phenyl, thienyl, or furyl group, optionally substituted with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group, or halogen atom;
- R⁴ and R⁵ independently stand for hydrogen atom, C₃₋₆ cycloalkyl group,
- 10 straight or branched C₁₋₄ alkyl group - optionally containing an amino group, or an amino group substituted with one or two straight or branched C₁₋₄ alkyl group, a hydroxy group, a carboxy group, or an alkoxy group substituted with a straight or branched C₁₋₄ alkyl group -;
- or
- 15 R⁴ stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group or a benzyl group, and
- R⁵ stands for hydrogen atom, -SO₂OH group or a straight or branched C₁₋₄ acyl group, or
- R⁴ and R⁵, together with the nitrogen atom, form a group of the general
- 20 formula a.), wherein R⁷ and R⁸ independently stand for hydrogen atom, straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group;
- R⁶ stands for hydrogen atom or straight or branched C₁₋₄ alkyl group, phenyl, benzyl, thienyl, or furyl group, optionally substituted with a methylenedioxy group, or with one or more straight or branched
- 25 C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group, hydroxy group, trifluoromethyl group, cyano group, or halogen atom; or a six- or five-membered heteroaromatic ring containing one, two or three nitrogen atoms, or one nitrogen atom and one oxygen atom, or one

nitrogen atom and one sulphur atom, optionally substituted with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group or halogen atom;

5 X stands for -CH₂- group, -NH- group, -NR⁹- group, or sulphur atom, oxygen atom, sulpho group or sulphonyl group, wherein R⁹ represents a straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group;

Z stands for oxygen atom, sulphur atom, -CHR¹⁰-group or -NR¹¹- group, wherein R¹⁰ represents hydrogen atom, straight or branched C₁₋₄ alkyl group, or C₃₋₆ cycloalkyl group and R¹¹ represents hydrogen atom, 10 straight or branched C₁₋₄ alkyl group, C₃₋₆ cycloalkyl group, -SO₂OH group or a formyl group ;

n represents zero, 1 or 2;

m represents 1, 2, or 3;

o represents 1, 2, or 3;

15 p represents zero or 1;

r represents zero or 1,

and their salts, solvates, isomers (tautomers, desmotrops, optically active isomers) as well as the salts and solvates thereof.

20 3. Compounds of the general formula (I) according to claims 1.-2., wherein:

R¹ stands for hydrogen atom or methyl group;

R² stands for hydrogen atom or methyl group;

R³ stands for phenyl-, thienyl, or furyl group;

25 R⁴ and R⁵ independently stand for hydrogen atom, C₃₋₆ cycloalkyl group, straight or branched C₁₋₄ alkyl group - optionally containing an amino group, or an amino group substituted with one or two straight or branched C₁₋₄ alkyl group, a hydroxy group, a carboxy group, or an

alkoxy group substituted with a straight or branched C₁₋₄ alkyl group -;
or

R⁴ stands for hydrogen atom or a straight or branched C₁₋₄ alkyl alkyl group or a benzyl group, and

5 R⁵ stands for hydrogen atom, -SO₂OH group or a formyl group, or

R⁴ and R⁵, together with the nitrogen atom, form a group of the general formula a.), wherein R⁷ and R⁸ independently stand for hydrogen atom, straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group;

10 R⁶ stands for 4-methoxyphenyl, 3-methylphenyl, 3-methoxyphenyl, 3,4-methylenedioxyphenyl group, 4-fluorophenyl, 2-thienyl or 2-furyl group;

X stands for -NH- group, or oxygen atom;

Z stands for oxygen atom, sulphur atom, -CH₂- group, -NH- group or -NR¹¹- group, wherein R¹¹ represents a straight or branched C₁₋₄ alkyl group, C₃₋₆ cycloalkyl group, -SO₂OH group or formyl group and

n represents 1;

m represents 2;

o represents 2;

p represents zero;

20 r represents zero,

and their salts, solvates, isomers (tautomers, desmotrops, optically active isomers) as well as the salts and solvates thereof.

4. The following compounds according to claims 1.-3.:

25 4-Methoxy-N-[6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl]-benzamide

4-Methoxy-N-[6-(4-methylpiperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl]benzamide

- 4-Methoxy-N-(6-dimethylamino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide
- 3,4-Methylenedioxy-N-(6-dimethylamino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide
- 5 4-Fluoro-N-(6-dimethylamino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide
- 4-Methoxy-N-(6-(piperazin-1-yl)-4-benzylamino-3-cyanoquinolin-2-yl)benzamide
- 4-Methoxy-N-(6-amino-4-benzylamino-3-cyanoquinolin-2-yl)benzamide
- 10 N-[4-(benzylamino)-3-cyano-6-(4-formylpiperazin-1-yl)quinolin-2-yl]-4-methoxybenzamide
- 4-{4-(Benzylamino)-3-cyano-2-[(4-methoxybenzoyl)amino]quinolin-6-yl}piperazine-1-sulfonic acid
- 15 N-{3-Cyano-6-(formylamino)-4-[(2-thienylmethyl)amino]quinolin-2-yl}-4-methoxybenzamide
- N-{3-Cyano-6-(formylamino)-4-[(2-thienylmethyl)amino]quinolin-2-yl}-1,3-benzodioxole-5-carboxamide
- 20 N-[4-(Benzylamino)-3-cyano-6-(formylamino)quinolin-2-yl]-1,3-benzodioxole-5-carboxamide
- N-[4-(Benzylamino)-3-cyano-6-(formylamino)quinolin-2-yl]-4-methoxybenzamide
- 25 N-[4-(Benzylamino)-3-cyano-6-(formylamino)quinolin-2-yl]-4-methoxybenzamide
- N-{4-(Benzylamino)-3-cyano-6-[formyl(methyl)amino]quinolin-2-yl}-4-methoxybenzamide
- 30 N-{3-Cyano-6-[formyl(methyl)amino]-4-[(2-thienylmethyl)amino]quinolin-2-yl}-4-methoxybenzamide
- {3-Cyano-2-[(4-methoxybenzoyl)amino]-4-[(2-thienylmethyl)amino]quinolin-6-yl} methylsulfamic acid
- 35

{4-(Benzylamino)-3-cyano-2-[(4-methoxybenzoyl)amino]quinolin-6-yl}methylsulfamic acid

5 {4-(Benzylamino)-3-cyano-2-[(4-methoxybenzoyl)amino]quinolin-6-yl}sulfamic acid

[2-[(1,3-Benzodioxol-5-ylcarbonyl)amino]-4-(benzylamino)-3-cyanoquinolin-6-yl]sulfamic acid

10 {2-[(1,3-Benzodioxol-5-ylcarbonyl)amino]-3-cyano-4-[(2-thienylmethyl)amino]quinolin-6-yl}sulfamic acid

15 {3-Cyano-2-[(4-methoxybenzoyl)amino]-4-[(2-thienylmethyl)amino]quinolin-6-yl}sulfamic acid

and their salts, solvates, isomers (tautomers, desmotrops), as well as the salts and solvates thereof.

5. Process for the preparation of the compounds of the general formula (I)
20 and their salts, solvates and isomers, wherein in the formula the meanings of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , X, Z, n, o, p, r and m are as defined in claim 1., c h a r a c t e r i z e d i n t h a t,

v) a bis-carboxamide of the general formula (II"), wherein

$R^{1''}$ stands for hydrogen atom or a straight or branched C_{1-4} alkyl group;
25 $R^{2''}$ stands for hydrogen atom or a straight or branched C_{1-4} alkyl group;
 $R^{3''}$ stands for hydrogen atom, or a straight or branched C_{1-4} alkyl group, C_{3-6} cycloalkyl group, a phenyl, thienyl, or furyl group, optionally substituted with one or more straight or branched C_{1-4} alkyl group, straight or branched C_{1-4} alkoxy group, or halogen atom; a six- or five-
30 membered heteroaromatic ring containing one, two or three nitrogen atoms, or a five-membered heteroaromatic ring containing one nitrogen atom and one oxygen atom, or one nitrogen atom and one sulphur atom, optionally substituted with one or more straight or branched

C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group, or halogen atom;

5 R^{4''} and R^{5''} independently stand for hydrogen atom, C₃₋₆ cycloalkyl group, straight or branched C₁₋₄ alkyl group - optionally containing an amino group, or an amino group substituted with one or two straight or branched C₁₋₄ alkyl group, a hydroxy group, a carboxy group, or an alkoxy group substituted with a straight or branched C₁₋₄ alkyl group – or a protective group; or

10 R^{4''} stands for hydrogen atom or a straight or branched C₁₋₄ alkyl group or a benzyl group, and

R^{5''} stands for hydrogen atom, –SO₂OH group or a straight or branched C₁₋₄ acyl group or a protective group, or

15 R^{4''} and R^{5''}, together with the nitrogen atom, form a nitro group or a group of the general formula a.), wherein R^{7''} and R^{8''} independently stand for hydrogen atom, straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group;

20 R^{6''} stands for hydrogen atom or straight or branched C₁₋₄ alkyl group, phenyl, benzyl, thienyl, or furyl group, optionally substituted with methylenedioxy group, or with one or more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group, hydroxy group, trifluoromethyl group, cyano group or halogen atom; or a six- or five-membered heteroaromatic ring containing one, two or three nitrogen atoms, or one nitrogen atom and one oxygen atom, or one nitrogen atom and one sulphur atom, optionally substituted with one or
25 more straight or branched C₁₋₄ alkyl group, straight or branched C₁₋₄ alkoxy group or halogen atom;

X" stands for $-\text{CH}_2-$ group, $-\text{NH}-$ group, $-\text{NR}^{9"}$ group, or sulphur atom, oxygen atom, sulpho group or sulphony group, wherein $\text{R}^{9"}$ stands for straight or branched C_{1-4} alkyl group or C_{3-6} cycloalkyl group;

5 Z" stands for oxygen atom sulphur atom, $-\text{CHR}^{10"}$ -group or $-\text{NR}^{11"}$ -group, wherein $\text{R}^{10"}$ stands for hydrogen atom, straight or branched C_{1-4} alkyl group, or C_{3-6} cycloalkyl group and $\text{R}^{11"}$ stands for hydrogen atom, straight or branched C_{1-4} alkyl group, C_{3-6} cycloalkyl group, $-\text{SO}_2\text{OH}$ group or a straight or branched C_{1-4} acyl group ;

n" represents zero, 1 or 2;

10 m" represents 1, 2, or 3;

o" represents 1, 2, or 3;

p" represents zero or 1;

r" represents zero or 1,

is selectively hydrolysed and if desired the protective group removed, or

15 v/i.) for the preparation of a compound of the general formula (I), wherein R^4 stands for hydrogen atom, a straight or branched C_{1-4} alkyl group or benzyl group and R^5 stands for a straight or branched C_{1-4} acyl group, or R^4 and R^5 together with the nitrogen atom form a group of the general formula a.), wherein Z stands for a $-\text{NR}^{11}$ group, where R^{11} stands for a
20 straight or branched C_{1-4} acyl group and R^1 , R^2 , R^3 , R^6 , R^7 , R^8 , R^9 , X, n, m, o, p and r are as defined above,

a compound of the general formula (I), wherein R^4 stands for hydrogen atom, a straight or branched C_{1-4} alkyl group or benzyl group and R^5 stands for hydrogen atom, or R^4 and R^5 together with the nitrogen atom form a
25 group of the general formula a.), wherein Z stands for $-\text{NH}$ group and R^1 , R^2 , R^3 , R^6 , R^7 , R^8 , R^9 , X, n, m, o, p and r are as defined above,

is acylated with a compound of the general formula $\text{R}^{12"}\text{COY}''$, wherein $\text{R}^{12"}$ and Y'' are as defined above, or

v/ii.) for the preparation of a compound of the general formula (I), wherein R^4 stands for hydrogen atom, a straight or branched C_{1-4} alkyl group or benzyl group and R^5 stands for $-SO_2OH$ group, or R^4 and R^5 together with the nitrogen atom form a group of the general formula a.), wherein Z stands
 5 for $-NR^{11}$ - group, where R^{11} stands for $-SO_2OH$ group and $R^1, R^2, R^3, R^6, R^7, R^8, R^9, X, n, m, o, p$ and r are as defined above,

a compound of the general formula (I), wherein R^4 stands for hydrogen atom, a straight or branched C_{1-4} alkyl group or benzyl group and R^5 stands for hydrogen atom, or R^4 and R^5 together with the nitrogen atom form a
 10 group of the general formula a.), wherein Z stands for $-NH-$ group and $R^1, R^2, R^3, R^6, R^7, R^8, R^9, X, n, m, o, p$ and r are as defined above,

is reacted with a pyridine- SO_3 complex, or with $ClSO_3H$, or

v/iii.) for the preparation of a compound of the general formula (I), wherein R^4 stands for hydrogen atom, a straight or branched C_{1-4} alkyl group or
 15 benzyl group and R^5 stands for $-SO_2OH$ group and $R^1, R^2, R^3, R^6, R^7, R^8, R^9, X, Z, n, m, o, p$ and r are as defined above,

a compound of the general formula (XIII"), wherein $R^1, R^2, R^3, R^6, R^9, X$, and n are as defined above

is reacted with $Na_2S_2O_4$ or $NaHSO_3$,

20 or

is reduced and the compound of the general formula (XIV"), thus obtained, wherein $R^{4''}$ stands for hydrogen atom and $R^{1''}, R^{2''}, R^{3''}, R^{6''}, R^{9''}, X'',$ and n'' , are as defined above, is sulphated with a pyridine- SO_3 complex or with $ClSO_3H$,

25 if desired after transforming the $R^{4''}$ hydrogen atom into a straight or branched C_{1-4} alkyl group or a benzyl group, or

v/iv.) for the preparation of a compound of the general formula (I), wherein R^4 stands for hydrogen atom, C_{3-6} cycloalkyl group, benzyl group, straight or

branched C₁₋₄ alkyl group - optionally containing an amino group, or an amino group substituted with one or two straight or branched C₁₋₄ alkyl group, a hydroxy group, a carboxy group, or an alkoxy group substituted with a straight or branched C₁₋₄ alkyl group and R⁵ stands for hydrogen atom, or
 5 R⁴ and R⁵, together with the nitrogen atom, form a group of the general formula a.), wherein R⁷ and R⁸ independently stand for hydrogen atom, straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group and Z stands for -NR¹¹ - group, where R¹¹ stands for hydrogen atom,

removing the protective group of a compound of the general formula
 10 (I''), wherein
 R^{4''} stands for hydrogen atom, C₃₋₆ cycloalkyl group, benzyl group, straight or branched C₁₋₄ alkyl group - optionally containing an amino group, or an amino group substituted with one or two straight or branched C₁₋₄ alkyl group, a hydroxy group, a carboxy group, or an alkoxy group substituted with
 15 a straight or branched C₁₋₄ alkyl group- and R^{5''} stands for a protective group, or
 R^{4''} and R^{5''}, together with the nitrogen atom, form a group of the general formula a''), wherein R^{7''} and R^{8''} independently stand for hydrogen atom, straight or branched C₁₋₄ alkyl group or C₃₋₆ cycloalkyl group and Z stands for
 20 -NR^{11''} group, where R^{11''} stands for a protecting group,
 and-if desired- the substituents of the resulting compound of the general formula (I) are transformed into each other by known methods, and/or the the compound of the general formula (I) thus obtained is transformed into its salt or solvate, or liberated from its salt or solvate and -if desired- resolved into
 25 its optically active isomers and -if desired- a given desmotrop is transformed into an other desmotropic form.

6. Process according to claim 5., characterized in that the selective hydrolysis is effected with alkali hydroxide dissolved in alcoholic medium, preferably with methanolic potassium- or sodium hydroxide solution.
- 5 7. Pharmaceutical composition, characterized in that it contains one or more compounds of the general formula (I), -where in the formula $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, X, Z, n, m, o, p$ and r have the meaning as defined in Claim 1.- and/or their salts, solvates, isomers (tautomers, desmotrops, optically active isomers) the salts, solvates thereof, and one or more auxiliary
- 10 materials, commonly used in the pharmaceutical industry.
8. Pharmaceutical composition as defined in claim 7., characterized in that it contains as active substance one or more of the compounds defined in claim 3.
- 15 9. Use of the compounds of the general formula (I), their salts, solvates and isomers, -where in the formula $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, X, Z, n, m, o, p$, and r have the meaning as defined in claim 1.- for the manufacture of a pharmaceutical composition for the treatment of diseases in
- 20 development of which the receptor A_3 plays a role.
10. Use of the compounds of the general formula (I) their salts, solvates and isomers, -where in the formula $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, X, Z, n, m, o, p$, and r have the meaning as defined in claim 1.- according to claim 9
- 25 as A_3 ligand for the manufacture of a pharmaceutical composition for the treatment of diseases of the heart, kidney, respiratory organs and central nervous system, and for the inhibition of the protection of adenosine in growing tumor cells, prevention of mast cell degranulation, inhibition of

the cytokine production, reduction of intraocular pressure, inhibition of the $\text{TNF}\alpha$ release, inhibition of eosinophil, neutrophil and other immune cell migration., inhibition of bronchoconstriction and plasma extravasation.

5

11. Use of the compounds of the general formula (I), their salts, solvates and isomers, -where in the formula $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{X}, \text{Z}, \text{n}, \text{m}, \text{o}, \text{p},$ and r have the meaning as defined in claim 1.- according to claim 10 as A_3 receptor antagonist for the manufacture of antiinflammatory, antiasthmatic, antiischemic, antidepressant, antiarrhythmic, renal protective, antitumor, antiparkinson and cognitive enhancing pharmaceutical compositions and compositions for the treatment or prevention of myocardial reperfusion injury, chronic obstructive pulmonary disease (COPD) and adult respiratory distress syndrome (ARDS) including chronic bronchitis, pulmonary emphysema or dyspnea, allergic reactions (e.g. rhinitis, poison ivy induced responses, urticaria, scleroderma, arthritis) other autoimmune diseases, inflammatory bowel disease, Addison's disease, Crohn's disease, psoriasis, rheumatism, hypertension, neurological function disorders, glaucoma and diabetes.

20

12. Use of the compounds of the general formula (I), their salts, solvates and isomers, -where in the formula $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{X}, \text{Z}, \text{n}, \text{m}, \text{o}, \text{p},$ and r have the meaning as defined in claim 1.- according to claims 10 and 11 as A_3 receptor antagonist for the manufacture of a pharmaceutical composition for the treatment of diseases such as asthma, COPD and ARDS, glaucoma, tumor, allergic reactions, inflammatory diseases, ischemia, hypoxia, arrhythmia and renal diseases.

25

13. Compounds of the general formula (I"), where in the formula the meanings of $R^{1''}$, $R^{2''}$, $R^{3''}$, $R^{6''}$, $R^{7''}$, $R^{8''}$, X'' , n'' , m'' , o'' , p'' , and r'' are as defined in claim 5. and
- $R^{4''}$ stands for hydrogen atom, C_{3-6} cycloalkyl group, benzyl group, straight or branched C_{1-4} alkyl group - optionally containing an amino group, or an amino group substituted with one or two straight or branched C_{1-4} alkyl group, a hydroxy group, a carboxy group, or an alkoxy group substituted with a straight or branched C_{1-4} alkyl group- and $R^{5''}$ stands for a protective group, or
- 10 $R^{4''}$ and $R^{5''}$, together with the nitrogen atom, form a group of the general formula a ".), wherein $R^{7''}$ and $R^{8''}$ independently stand for hydrogen atom, straight or branched C_{1-4} alkyl group or C_{3-6} cycloalkyl group and Z stands for $-NR^{11''}$ group, where $R^{11''}$ stands for a protecting group.
- 15 14. Compounds of the general formula (II"), where in the formula the meanings of $R^{1''}$, $R^{2''}$, $R^{3''}$, $R^{4''}$, $R^{5''}$, $R^{6''}$, $R^{7''}$, $R^{8''}$, X'' , Z'' , n'' , m'' , o'' , p'' , and r'' are as defined in claim 5.
15. Compounds of the general formula (III"), where in the formula the
- 20 meanings of $R^{1''}$, $R^{2''}$, $R^{3''}$, $R^{4''}$, $R^{5''}$, $R^{7''}$, $R^{8''}$, X'' , Z'' , n'' , m'' , o'' , p'' , and r'' are as defined in claim 5.
16. Compounds of the general formula (IV") where in the formula the meanings of $R^{4''}$, $R^{5''}$, $R^{7''}$, $R^{8''}$, Z'' , m'' , o'' , p'' , and r'' are as defined
- 25 in claim 5.
17. Compounds of the general formula (V"), where in the formula the meanings of $R^{4''}$, $R^{5''}$, $R^{7''}$, $R^{8''}$, Z'' , m'' , o'' , p'' , and r'' are as defined in claim 5.

18. Compounds of the general formula (VI"), where in the formula the meanings of $R^{4''}$, $R^{5''}$, $R^{7''}$, $R^{8''}$, Z'' , m'' , o'' , p'' , and r'' are as defined in claim 5., with the proviso that $R^{4''}$ and $R^{5''}$ together with the nitrogen atom, have a
5 meaning different from dimethylamino- and amino group.

19. Compounds of the general formula (VII"), where in the formulae the meanings of $R^{4''}$, $R^{5''}$, $R^{7''}$, $R^{8''}$, Z'' , m'' , o'' , p'' , and r'' are as defined in claim 5., with the proviso that $R^{4''}$ and $R^{5''}$ together with the nitrogen, atom have a
10 meaning different from dimethylamino-, diethylamino-, and amino group.

20. Compounds of the general formula (VIII"), where in the formula $R^{4''}$ and $R^{5''}$ together with the nitrogen atom, represent a morpholino, N-methylpiperazino, piperazino or 4-benzylpyperazino group.

15

21. Compounds of the general formula (XIII"), wherein the meanings of the substituents $R^{1''}$, $R^{2''}$, $R^{3''}$, $R^{6''}$ and n'' are as defined in claim 5.